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1Summary  
 
Among the oligonucleotides analogues Peptide Nucleic Acids (PNAs) are the most 
powerful, with a N-(2-amino-ethyl)-glycine unit replacing the sugar-phosphate 
backbone.1 They show strong and sequence specific hybridisation to complementary 
single stranded DNA and RNA2 as well as to double stranded DNA by triplex formation.3
In addition, this kind of DNA mimic is not degraded by nucleases and proteases4 and 
was shown to have both good antisense and antigene activity.5
Although they have truly remarkable binding properties, pure PNAs present some 
problems: a limited water solubility and the inability to interact with DNA-binding 
proteins. 
On the other hand chimeric molecules composed of a DNA region protected by a PNA 
moiety at 3’ and/or 5’ end (PNA/DNA chimeras) retain a good water solubility and the 
ability of DNA to interact with DNA-binding proteins; moreover, like PNAs, they are 
resistant to the exonuclease degradation. 
PNA-DNA chimeras can be recognized by the DNA polymerase and can be used as 
primers for PCR reactions6; furthermore, double stranded molecules based on PNA-
DNA chimeras bind to transcription factors in a sequence-dependent manner7
Despite their interesting characteristics, in vivo biological studies of PNA-DNA chimeras 
have been so far limited because of the difficulties associated with obtaining them in 
good amount, due to the synthetic problems in the routes to the monomers, linkers and 
oligomers. In the first part of my PhD thesis, I address this problem, as furthermore 
discussed in the next sections. 
The second part of my thesis deals with the resolution of a different problem related to 
the usage of PNA/DNA chimeras in diagnostic applications. Specifically, the addressed 
problem is the production of a chimera which retains its diagnostic power, without risking 
of acting an antisense in the cellular contest. The selected diagnostic approach is that of 
the molecular beacons. 
 
1 a) Nielsen, P. E.; Egholm, M.; Berg, R. M.; Buchardt, O. Science 1991, 254, 1497; b) Egholm, M.; 
Buchardt, O.; Nielsen, P. E.; Berg, R. H. J Am Chem Soc 1992, 114, 1895; c) Nielsen, P. E.; Egholm, M.; 
Buchardt, O. Bioconjug Chem, 1994, 5, 3; d) Uhlmann, E.; Peyman, A.; Breipohl, G.; Will, D. W. Angew 
Chem Int Ed 1998, 37, 2796. 
2 Egholm, M.; Buchardt, O.; Christensen, L.; Behrens, C.; Freier, S. M.; Driver, D. A.; Berg, R. H.; Kim, S. 
K.; Norden B.; Nielsen, P. E. Nature 1993, 365, 566. 
3 Nielsen, P. E.; Egholm, M.; Buchardt, O. J Mol Recognit 1994, 7, 165. 
4 Demidov, V. V.; Potaman, V. N.; Frank-Kamenetskii, M. D.; Egholm, M.; Buchard, O.; Sonnichsen, S. H.; 
Nielsen, P. E. Biochem Pharmacol 1994, 48, 1310-3. 
5 a) Buchardt, O.; Egholm, M.; Berg R. H.; Nielsen, P. E. Trends in Biotechnology 1993, 11, 384-6; b) 
Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. Anti-Cancer Drug Design 1993, 8, 53; c) Nielsen, P. 
E.; Egholm, M. Curr Issues Mol Biol 1999, 1, 89. Gambari, R. Curr Pharm Des 2001, 7, 1839; d) Nielsen, 
P. E. Curr Opin Mol Ther 2000, 2, 282; e) Ray, A.; Norden, B. Faseb J 2000, 14, 1041. 
6 Uhlmann, E.; Will, D. W.; Breipohl, G.; Langner, D.; Ryte, A. Angew Chem Int Ed 1996, 35, 2632. 
7 Uhlmann, E. Biol Chem 1998, 379, 1045. 
2A molecular beacon8 is a DNA single strand composed of a loop region with a sequence 
complementary to the target DNA and a stem region in which the nucleotides are paired 
in a double strand. On the 5'- or 3'-terminus, respectively, a fluorophore and a quencher 
are linked. Fluorescence is quenched as long as the stem region is paired in a double 
strand. Upon their binding to complementary targets, molecular beacons adopt an open 
conformation in which the labels are spatially separated. As a result, molecular beacons 
brightly fluoresce in the presence of nucleic acid target sequences. 
In order to protect the DNA loop from exonuclease degradation and avoid non specific 
sequence recognition by the stem region, we propose to use an alanyl peptide nucleic 
acid double stranded (alanyl-PNA) as the stem of a molecular beacon keeping the DNA 
recognition loop. Since the alanyl-PNA pairing system is orthogonal to oligonucleotides 
with respect to double strand formation, the overall system will have greater specificity 
and no risk of inducing an antisense effect due to the stem. 
 
8 a) S. Tyagi, F. R. Kramer, Nat. Biotechnol. 1996, 14, 303. b) S. Tyagi, D. Bratu, F. R. Kramer, Nat. 
Biotechnol. 1998, 16, 49; b) G. P. Pfeifer, Technologies for Detection of DNA damage and mutations,
Plenum, New York, 1996; c) G. R. Taylor, Laboratory methods for the detection of mutations and 
polymorphisms in DNA, CRC Press, Boca Raton, Fla, 1997; d) V. V. Didenko, In situ detection of DNA 
damage: Methods and protocols, Humana Press, Totowa, New Jersey, 2002; e) W. Tan, X. Fang, J. Li, X. 
Liu, Chem. Eur. J. 2000, 6, 1107. 
 
3Riassunto  
 
Questo lavoro di tesi riguarda la sintesi di molecole ibride composte da porzioni di DNA 
e da altre a base di Acidi Peptido Nucleici (detti PNA da Peptide Nucleic Acids), dette 
Chimere PNA-DNA, e alcune possibili applicazioni biotecnologiche di queste utili 
molecole nell'ambito ambito terapeutico e diagnostico.  
I PNA sono analoghi oligonucleotidici basati su un’unità ripetitiva di N-(2-
amminoetil)glicina che porta la base eterociclica legata all’atomo di azoto della glicina 
mediante un ponte metilencarbonilico. I PNA riconoscono DNA ed RNA complementari 
in maniera specifica formando complessi molto stabili obbedendo allo schema di legame 
ad idrogeno di Watson-Crick con un’affinità maggiore rispetto ad oligonucleotidi 
convenzionali. Inoltre, il loro scheletro pseudopeptidico conferisce loro stabilità chimica e 
resistenza a degradazione enzimatica da parte di nucleasi o proteasi. 
 
I PNA sono molto interessanti dal punto di vista biologico come agenti antisenso, per la 
loro capacità di inibire la traduzione riconoscendo mRNA complementari, come agenti 
antigene, per la modulazione della trascrizione e replicazione, come anticancro, in 
quanto inducono la riduzione di attività delle telomerasi. Altra applicazione consiste 
nell’individuazione di mutazioni genetiche, come nel caso della rivelazione del gene 
CFTR nella fibrosi cistica. I PNA, spostando singoli filamenti di DNA in duplex,
permettono l’idrolisi di questi filamenti da parte di nucleasi specifiche. Si possono 
ottenere, perciò, degli enzimi di restrizione artificiali usando la nucleasi opportuna in 
combinazione con molecole di PNA. Nonostante le loro notevoli proprietà di ibridazione i 
PNA presentano alcuni limiti. Infatti, dato il loro carattere neutro, questi analoghi 
oligonucleotidici risultano scarsamente solubili in acqua. Inoltre, proteine regolative che 
normalmente si legno al DNA, non sono però in grado di interagire con i PNA. Infatti, 
come dimostrato da strudi strutturali, doppie eliche tra PNA ed acidi nucleici naturali o 
PNA/PNA mostrano una struttura molto diversa da quella delle corrispondenti duplex 
naturali. 
 
4Una possibile strategia per poter utilizzare oligonucleotidi per il legame con proteine 
regolative, in applicazioni in vivo, si basa sulla sintesi di sistemi misti in cui il DNA si 
trova protetto alle estremità 5’ e 3’ da porzioni di PNA. In questo modo si combinano la 
stabilità enzimatica dei PNA alla capacità del DNA di interagire con proteine, rendendo 
questi ibridi anche più solubili in acqua e migliorando l’uptake cellulare. Risultati 
incoraggianti provengono dall’utilizzo in vitro con un approccio decoy di duplex 
chimeriche PNA-DNA in grado di interagire stabilmente con il fattore nucleare NF-kB 
che gioca un ruolo chiave nel processo di trascrizione del genoma di HIV-1 legando la 
sequenza regolativa HIV-LTR (long terminal repeat). [Curr Drug Targets. 2004 
Nov;5(8):735-44 Peptide nucleic acids (PNA)-DNA chimeras targeting transcription 
factors as a tool to modify gene expression. Borgatti M, Finotti A, Romanelli A, Saviano 
M, Bianchi N, Lampronti I, Lambertini E, Penolazzi L, Nastruzzi C, Mischiati C, Piva R, 
Pedone C, Gambari R.] 
Nella prima parte della tesi si affronta l’interazione di chimere PNA/DNA con HMGB1, 
una proteina coinvolta in molti processi infiammatori come potente citochina e 
considerata, pertanto, un target terapeutico di grande interesse. HMGB1 è una proteina 
con una sequenza amminoacidica molto conservata tra i mammiferi ed è nota come 
proteina coinvolta nel mantenimento della struttura del nucleosoma e nella regolazione 
della trascrizione genica. La struttura di HMGB1 comprende  tre domini: due domini per 
il legame del DNA (Box A e Box B) ed un’estremità carbossilica (coda acida). In 
particolare i domini Box A e Box B hanno una forma angolata (o a “L”) e sono 
responsabili del legame di HMGB1 al minor groove del DNA, causando una locale 
distorsione della doppia elica. 
 
5HMGB1 è secreta attivamente da monociti e macrofagi (rilascio specifico) ma è anche 
rilasciata passivamente da cellule necrotiche (rilascio non specifico). Questi due percorsi 
sono fondamentali per l’attività di HMGB1 come citochina. La secrezione di HMGB1 
sembra essere indotta da due segnali ed aver luogo attraverso tre step: all’inizio un 
segnale infiammatorio promuove l’acetilazione di HMGB1, la sua rilocazione dal nucleo 
al citoplasma (step 1) ed il suo accumulo nelle vescicole secretorie presenti nel 
citoplasma (step 2); successivamente un segnale di secrezione (ATP extracellulare o 
lisofosfatidilcolina) promuove l’esocitosi (step 3) [Andersson et al., 2002; Scaffidi et al. 
2002; Bonaldi et al., 2003; Friedman et al., 2003; Gardella et al., 2002].  
Extracellularmente HMGB1 lega i recettori RAGE, TLR2 e TLR4 attivando diversi 
processi infiammatori. Perciò agenti terapeutici in grado di inibire il rilascio o l’azione di 
HMGB1 conferiscono una protezione significativa contro sepsi, endotossiemia ed artrite 
in modelli animali permettendo di affrontare così varie patologie infiammatorie. 
La strategia presentata in questa tesi per l’inibizione di HMGB1 si basa su uno scambio 
di ligandi. In altre parole l’idea consiste nell’usare il ligando nucleare di HMGB1 (cioè il 
DNA) al di fuori della sua locazione naturale in modo da antagonizzare i ligandi 
extracellulari nel riconoscimento della stessa HMGB1 ed evitare gli effetti pro-
infiammatori di questa citochina. 
 
In questa strategia anti-HMGB1 inizialmente sono state considerate alcune duplex di 
DNA che presentavano una struttura preventivamente piegata in modo da trovarsi già 
nella condizione favorevole per l’interazione di legame con HMGB1. Sulla base di 
sequenze note in letteratura di DNA in legame con proteine omologhe di HMGB1, sono 
stati disegnate le seguenti sequenze di DNA: 
 
24-mer  3’ OH-GTTGCATTGAAAAAATTTCTTAGG-5’OH       6A 
18-mer 5’OH-CAACGTAAC - - - - - - AAAGAATCC-3’OH 
 
22-mer  3’OH-GTTGCATTGAAAATTTCTTAGG-5’OH   4A 
18-mer 5’OH-CAACGTAAC - - - -AAAGAATCC-3’OH 
 
20-mer 3’OH-GTTGCATTGAATTTCTTAGG-5’OH    2A 
18-mer 5’OH-CAACGTAAC - - AAAGAATCC-3’OH  
 
18’-mer 3’OH-GTTGCATTGTTTCTTAGG-5’OH    0A 
18-mer 5’OH-CAACGTAACAAAGAATCC-3’OH  
 
Nel caso di 6A, 4A e 2A i due filamenti, di differente lunghezza, risultano complementari 
a meno del tratto poliadeninico (dA6, dA4 e dA2) nella parte centrale di uno dei due al 
fine di indurre una piegatura nella stuttura del DNA in forma duplex (bent duplex): 
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La duplex 0A (perfettamente complementare) è servita come riferimento in esperimenti 
effettuati successivamente.  
Studi di modelling effettuati usando come dati di partenza le strutture note in letteratura 
di complessi di regioni omologhe a Box B con duplex di DNA sono stati eseguiti sulle 3 
bent duplex. Da questi studi è stato evidenziato innanzitutto che la piegatura nelle 
duplex non è un effetto dovuto solo al legame con la proteina ma è già intrinsecamente 
dovuto alla presenza del bulge.
E’ stato inoltre possibile rivelare una maggiore stabilità per la duplex 2A che presenta un 
maggior contributo di stacking per adenina contenuta nel bulge (nella struttura piegata 
del 2A si ha perdita dell’interazione tra una coppia di basi T-A, ma si ha un effetto 
stabilizzante di stacking tra le basi T-A-A impilate le une sulle altre). Nel caso di 4A solo 
3 adenine su 4 nel bulge danno luogo allo stacking e si ha perdita dell’interazione tra 
una coppia di basi C-G (con perdita di ben 3 legami H). Nel caso del 6A non è stato 
possibile ottenere nessuna struttura stabile che contenesse un bulge con 6 adenine. In 
2A duplex           4A duplex 
7conclusione dagli studi di modelling è stato possibile dedurre che la duplex 2A, che 
presenta il contributo di stacking per adenina maggiore, è quella più stabile. 
I DNA progettati sono stati ottenuti mediante sintesi in fase solida su un sintetizzatore 
automatico Expedite 8909, utilizzando come supporto solido una resina CPG, 
funzionalizzata con il primo monomero nucleotidico all’estremità 3’. Utilizzando tali 
filamenti, mediante procedure di annealing, sono state ottenute le duplex corrispondenti.  
Le duplex così ottenute sono state studiate mediante Dicroismo Circolare (CD) in 
esperimenti che hanno rivelato l’andamento di stabilità gia previsto dal modelling con 
una diminuzione della stabilità all’aumentare delle dimensioni del bulge. Gli “spettri dei 
bulge” sono stati, inoltre, ottenuti sottraendo lo spettro CD dello 0A  a quelli relativi a 6A, 
4A e 2A e normalizzando per il numero di A presenti nel bulge.
Da questi esperimenti è stato evidenziato che il contributo di stacking per adenina risulta 
più grande nel caso del 2A, come già previsto dagli studi di modelling.
La formazione dei complessi con la proteina per 6A, 4A e 2A è stata dimostrata dal fatto 
che gli spettri relativi alla somma dei contributi CD di proteina e DNA risultano differenti 
da quelli ottenuti dopo il mescolamento, mediante speciali cuvette a doppia camera. 
La maggiore differenza ottenuta sottraendo i due spettri si ha nel caso del 6A che 
rappresenta la bent duplex che richiede la maggiore riorganizzazione strutturale per 
poter legare HMGB1.  
La stabilità termica dei complessi proteina/bent DNA è stata ottenuta mediante 
esperimenti di melting via CD. Anche nel caso dei complessi, la stabilità diminuisce 
all’aumentare della lunghezza del bulge, come evidenziato dalle Tm che rispecchiano 
l’andamento dei DNA non legati. 
 
8Il complesso duplex/HMGB1 più stabile risulta quindi essere quello relative al 2A con 
una Tm di 40 °C. Proprio sul 2A è stata effettuata la titolazione con la proteina per 
studiare la affinità di legame (Kd = 25 10-9 M). 
Il miglior candidato per l’utilizzo terapeutico anti-HMGB1 risulta quindi essere la duplex 
piegata contenente 2 adenine. Non è però possibile utilizzare tale duplex formata da 
DNA naturale in vivo, in quanto verrebbe velocemente degradato. Abbiamo quindi 
realizzato una duplex chimerica PNA/DNA per ottenere maggiore resistenza all’azione 
degradativa delle nucleasi seriche. Tali chimere sono formate da due filamenti di DNA 
contenenti una porzione di PNA all’estremità 3’(5’DNA-PNA3’). Le chimere 3’ risultano 
più resistenti alla degradazione enzimatica rispetto alle corrispondenti PNA-5’DNA3’, 
poiché in siero le 3’ esonucleasi sono più abbondanti delle 5’ esonucleasi22.
La duplex chimerica col bulge contenente 2 adenine è stata ottenuta grazie alla sintesi 
dei seguenti filamenti: 
 
20-mer COOH-ctt*GCATTGAATTTCTTAGG-5’OH   Chim 2A 
18-mer 5’OH-GAACGTAAC - - AAAGAA*tcc-COOH 
 
Esperimenti di spettroscopia UV e CD sono stati effettuati per verificare la formazione 
della duplex e per determinare la temperatura di melting. Inoltre da studi di stabilità 
enzimatica in siero umano è stato dimostrato che la duplex Chim 2A risulta 18 volte più 
resistente della duplex naturale corrispondente. 
L’inibizione di HMGB1 da parte di Chim 2A è stata verificata mediante esperimenti 
cellulari (su cellule BAEC) in cui la migrazione e proliferazione cellulare indotta da 
HMGB1 è ridotta drasticamente in presenza di Chim 2A (IC50~10 nmol/L). 
Infine migliorando i protocolli sintetici relativi all’ottenimento di monomeri di PNA 
tritilati(nota), compatibili con la sintesi del DNA, ed ottimizzando i protocolli per 
l’ottenimento di filamenti chimerici su larga scala, è stato possibile ottenere quantità di 
duplex chimeriche sufficienti per esperimenti in vivo, mai realizzati prima d’ora su 
chimere PNA/DNA. 
La seconda parte di questa tesi, sviluppata presso l’Institut für Organische und 
Biomolekulare Chemie della Georg-August-Universität di Göttingen sotto la direzione del 
Prof. Dr. Ulf Diederichsen, tratta di chimere alanil PNA-DNA-alanil PNA da utilizzarsi in 
diagnostica molecolare in un approccio di molecolar beacon (nota) per la rivelazione di 
sequenze oligonucleotidiche. 
 
3.54.683.41Tm
40.539.0834.81Tm Comp
36.9934.4031.40Tm Free
2A4A6A
9La novità rispetto ai molecular beacon tradizionali (a base cioè unicamente di DNA, 
lettera A in figura) risiede nella possibilità di evitare fenomeni di riconoscimento non 
specifico dovuti allo stem grazie al fatto che gli alanil PNA sono in grado di formare 
complessi stabili con alanil PNA complementari (seguendo lo schema di legame ad 
idrogeno di Watson-Crick), ma non ibridano sequenze oligonucleotidiche naturali 
complementari. In questo modo si ha apertura del molecolar beacon, e comparsa del 
fenomeno della fluorescenza, unicamente in seguito al riconoscimento di sequenze 
target da parte del loop.
Altre caratteristiche utili di questo sistema diagnostico innovativo sono l’utilizzo di una 
guanina come quencher e la protezione dalla degradazione nucleasica in siero del 
sistema dovuta alla presenza dei tratti di alanil PNA.  
E’ stata dunque effettuata la sintesi dei nuovi monomeri di alanil PNA (1-4) con 
protezioni Mmt (Monometossitritile)/acile e pertanto adatti alla sintesi di chimere alanil 
PNA/DNA, per tutte e quattro le basi azotate. 
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10 
La sintesi enantioselettiva descritta in questa tesi parte dal lattone della (L)-Boc Serina e 
ha fornito i quattro monomeri, dopo rimozione del gruppo Boc e riprotezione con il 
gruppo Mmt, già pronti per la sintesi in fase solida delle chimere il cui assemblaggio è al 
momento in corso di realizzazione presso una azienda privata per conto dello stesso 
ateneo tedesco. 
11 
PART 1  
 
PNA/DNA chimeras for the inhibition of HMGB1, a DNA-binding protein involved in 
inflammatory processes 
12 
1.1 The therapeutic target: HMGB1 protein  
 
1.1.1 Introduction. 
 
Sepsis, a lethal systemic inflammatory response to infection, is a severe illness affecting 
nearly 750,000 patients in the United States annually with a mortality of 30% and for this 
reason is among the top ten causes of death in the United States today. A series of 
recent discoveries showed the importance of cytokines, circulating factors produced by 
the innate immune system, acting as mediators of sepsis-related tissue injury and death. 
Many resources have been expended to elucidate the pathologic mechanisms that 
underlie sepsis and to develop appropriate and effective therapeutics. Unfortunately 
even a slight delay in administration of therapeutics targeting inflammatory mediators 
renders most approaches ineffective; for this reason, to date, no anti-inflammatory agent 
has been clinically approved for the treatment of sepsis. These and other findings, 
described in part in the following discussion, have suggested that successful clinical 
management of sepsis may be dependent on targeting, in a broader therapeutic 
window, those agents identified as late-acting, downstream lethal mediators. One of 
these candidate mediators of delayed lethality is high mobility group box 1 (HMGB1 
formerly known as HMG-1), a cellular and nuclear protein that is now recognized as a 
cytokine and experimental therapeutic target.  
Recently an improved understanding was achieved of the pathogenic mechanisms in 
the field of sepsis. In the early stages, for instance, bacterial endotoxins stimulate cells 
of the innate immune system wich release pro-inflammatory cytokines (TNF, IL-1[ and 
IL-6). These early cytokines, in turn, induce the release of a later acting downstream 
mediator – identified as the known protein HMGB1 – that triggers the pathological 
sequelae mediated by the subsequent release of cytokines like TNF, IL-1[, IL-1], IL-
1Ra, IL-6, IL-8, etc., leading to a multisystem pathogenesis or to a lethal systemic 
inflammation9. Furthermore, other proteins belonging to the family of HMG-proteins and 
able to bend DNA are released together with HMGB1 in the extracellular medium. These 
proteins are inter alia HMGB2, HMGB3, HMG-1L10, HMG-4L and SP100-HMG. They 
share with HMGB1 highly homologous amino acid sequences. Like HMGB1, they 
trigger/sustain inflammatory pathologies interacting with the same receptors and leading 
to the same downstream pathways of interaction 
 
9 Andersson, U., Erlandsson-Harris, H., Yang, H and Tracey, K.J. (2002) HMGB1 as a DNA-binding 
cytokine. J. Leukocyte Biol., 72:1084-1091 
13 
Figure 1: HMGB1 is made of three independent domains. 
 
HMGB1, formerly named HMG1 but also known as amphoterin and sulphoglucuronyl 
carbohydrate-binding protein [SBP-1], together with homologous HMGB2 is an abundant 
( 106 molecules/cell), ubiquitous protein present in the nucleus (where it is associated 
with eukaryotic chromatin) and in the cytoplasm of mammalian cells. HMGB1 
homologous proteins are present in organisms other than vertebrates (e.g. HMGD in 
Drosophila melanogaster, Nhp6A in Saccharomyces cerevisiae, HMGa in maize) and 
have only a single HMG box which may (as in in Drosophila melanogaster) or may not 
(as in Saccharomyces cerevisiae) present an acidic tail. Single HMG-box domain 
proteins present in plants can contain basic extensions, at N-terminus and sometimesm 
at C-terminus of the HMG box, and short C-terminal acidic tails. HMG boxes, in single 
copies and not accompanied by acidic tails, are also found in several transcription 
factors10.
Figure 2 HMG family: HMGB1 and other homologous proteins. 
 
10 Biochem. Soc. Trans. (2001) 29, (395–401) HMG1 and 2: architectural DNA-binding proteins J. O. 
Thomas. 
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HMGB1 is only 10 times less abundant than core histones. It can be found in fibroblasts, 
neurons, hepatocytes, glia and in cells derived from hematopoietic stem cells, including 
monocytes/macrophages, neutrophils and platelets. HMGB1 protein is a ca. 25 kDa 
protein with a highly conserved sequence among mammals, whereby 2 out of 214 
amino acids have conservative substitutions in all mammalian species Its name means 
“High Mobility group Box 1” and simply derives from its electrophoretic mobility in SDS-
polyacrylamide gels. HMGB1 does not present any enzymatic activity on its own, but 
requires the assistance of other protein factors that in many cases show very little, if 
any, similarity in sequence or structure. It is traditionally known as a DNA binding protein 
involved in maintenance of nucleosome structure and regulation of gene transcription. 
HMGB1 molecule has a tripartite structure composed of three distinct domains: two DNA 
binding domains and an acid carboxyl terminus, making it bipolarly charged. 
 
1.1.2 Box A and Box B domains bind DNA. 
 
The three different domains that constitute HMGB1 structure are: two homologous DNA-
binding regions called Box A and Box B, having remarkably similar three dimensional 
structure, and a negatively charged C terminus (Acidic Tail). The structure that these two 
domains adopt in the complexes with DNAs comprises three [-helices (I, II and III) 
connected by two loops. Interactions of helices I and II, and interactions between helix III 
and the N-terminal strand are stabilised by clusters of highly conserved hydrophobic 
residues11.
11 Nature 399, 708 - 712 (17 June 1999); Basis for recognition of cisplatin-modified DNA by high-mobility-
group proteins Uta-Maria Ohndorf, Mark A. Rould, Qing HE, Carl O. Pabo & Stephen J. Lippard 
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Figure 3a Representation of Box B-DNA binding. 
 
Figure 3b DNA deformation induced by Box B-DNA binding. 
 
Every box domain shows an angular shape (or L shape) and allow HMGB1 to bind to 
the minor groove of DNA, causing a local distortion of the double helix. 
By this interaction the protein induces a DNA bend angle of 90-120°. Binding is not 
sequence–specific12. In the Box B domain resides the proinflammatory cytokine 
functionality of HMGB1, whereas the DNA-binding Box A region has an anti-
inflammatory effect and specifically antagonizes the activity of HMGB1.  
 
1.1.3 The role of HMGB1 protein in nuclear processes. 
 
For a long time, HMGB1 function was not clear and many research groups suggested 
different roles for this protein in nuclear processes as transcription, V(D)J recombination, 
DNA replication, DNA repair and nucleosome assembly. HMGB1 directly interacts with a 
 
12 Toshihiro Imamura, Hiroto Izumi, Gunji Nagatani, Tomoko Ise, Minoru Nomoto, Yukihide Iwamoto, and 
Kimitoshi Kohno J. Biol. Chem., Vol. 276, Issue 10, 7534-7540, March 9, 2001 
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number of proteins, including some HOX and POU domain transcription factors and the 
TATA-binding protein, and facilitate their binding through protein–protein interactions. 
HMGB1/2 were shown to enhance immunoglobulin V(D)J recombination by enforcing 
specific DNA recognition through their interaction with the RAG1/2 recombinase 
complex, and facilitating cleavage. 
HMGB1 plays an architectural role in DNA bending, looping, folding and wrapping by 
distorting, bending or modifying complexes of DNA structures with transcription factors 
or histones13.
As a nuclear protein, HMGB1 stabilizes nucleosomes and acts as a transcriptional 
regulatory molecule. In fact it causes DNA separation from the histone, in a mechanism 
seeing a key role of the Acidic Tail domain, and facilitates the binding of several 
transcriptional complexes. 
Through its DNA-binding domains HMGB1 binds DNA in a manner that does not 
depends on sequence, but on the presence of certain DNA structures including four-way 
junctions (cruciform DNA) and undertwisted DNA. HMGB1 protein facilitates self-ligation 
of short DNA fragments, and can bridge linear DNA fragments thereby enhancing 
multimerization of longer DNAs. Together with the closely related HMGB2 protein, 
HMGB1 has been implicated in a number of eukaryotic cellular processes mediated by 
DNA recognition including gene regulation, DNA replication and recombination. 
 
Figure 4 HMGB1-DNA interaction facilitates binding of transcription factors to DNA. 
 
13 a) Agresti, A. and Bianchi, M.E. (2003) HMGB-proteins and gene expression. Current Opin. In Genetics 
and Develop., 13: 170-178; b) Degryse, B., de Virgilio, M. (2003) The nuclear protein HMGB1, a new kind 
of chemokine ? FEBS Letters, 553:11-17 
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1.1.4 The extracellular presence of HMGB1 protein in serum. 
 
Beyond its intracellular location, HMGB1 is also found extracellularly. HMGB1 is actively 
secreted by monocytes and macrophages (specific release) but is also passively 
released from necrotic cells from any tissue (non specific release). These two pathways 
are fundamental for the activity of HMGB1 as a cytokine and provide key mechanisms 
integrating the inflammatory response to infectious and non-infectious cell injuries. 
Extracellular presence of HMGB1 is due to a mechanism in which inflammatory cells 
sense the tissue damage by recognising the presence of nuclear proteins in the 
extracellular milieu. Subsequently, during the evolution of the immune system 
specialised cells developed a signalling system that could lead to a strong inflammatory 
process by releasing HMGB1 following specific events, as outlined in the next few lines. 
In healthy cells, HMGB1 migrates to the cytoplasm both by passive and active transport. 
However, all cultured cells and resting monocytes contain the vast majority of HMGB1 in 
the nucleus, indicating that in basal conditions import is much more effective than 
export. Cells might transport HMGB1 from the nucleus by acetylating lysine residues 
which are abundant in HMGB1, thereby neutralizing their basic charge and rendering 
them unable to function as nuclear localization signals as was recently suggested by 
Bonaldi et al14. Nuclear HMGB1 hyperacetylation determines the relocation of this 
protein from the nucleus to the cytoplasm (in the fibroblasts, for example) or its 
accumulation into secretory endolysosomes (for example in monocytes and 
macrophages stimulated by IL-1, Ifn`, TNF[ or LPS) and subsequent redirection 
towards release through a non-classical vesicle mediated secretory pathway. HMGB1 
secretion by activated monocytes is triggered by bioactive lysophosphatidylcholine 
(LPC), which is generated later in the inflammation site from phosphatidylcholine 
through the action of the secretory phospholipase sPLA2, produced by monocytes 
several hours after activation. Therefore, secretion of HMGB1 seems to be induced by 
two signals14 and to take place through three steps: 1) at first, an inflammatory signal 
promotes HMGB1 acetylation and its relocation from the nucleus to the cytoplasm (step 
1) and storage into cytoplasmic secretory vesicles (step 2); then, a secretion signal 
(extracellular ATP or lysophosphatidylcholine) promotes exocytosis (step 3)9,14 
HMGB1 is released from activated innate immune cells or necrotic cells and functions as 
an important mediator of sepsis, endotoxemia, arthritis, and local inflammation. Thus, 
strategies targeting HMGB1 with specific antagonists or antibodies have big importance 
for treating lethal systemic inflammatory diseases characterized by excessive HMGB1 
release. 
 
14 a) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion Tiziana 
Bonaldi1,2, Fabio Talamo1, Paola Scaffidi3, Denise Ferrera4, Annalisa Porto1,5, Angela Bachi1, Anna 
Rubartelli4, Alessandra Agresti1,6, and Marco E. Bianchi3,6 The EMBO Journal, Vol. 22, No. 20 pp. 5551-
5560, 2003; b) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.Scaffidi, P., 
Misteli, T. and Bianchi, M.E. (2002) Nature, 418:191-195; c) The gesture life of high mobility group box 1. 
Friedman, S.G., Czura, C.J. and Tracey, K.J. (2003) Current Opinion in Clinical Nutrition and Metabolica 
Care, 6:283-287; d) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-
mediated secretory pathway.Gardella, S., Andrei, C., Ferrera, D., Lotti, L.V., Torrisi, M.R., Bianchi, M.E. 
and Rubarteli, A. (2002) EMBO. Rep., 3:995-1001 
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Therapeutic agents that inhibit HMGB1 action or release confer significant protection 
against sepsis, endotoxemia, and arthritis in animal models and thus hold potential for 
the clinical management of various inflammatory diseases.  
 
1.1.5 The role of HMGB1 protein as a cytokine. 
 
Extracellular HMGB1 acts as a powerful cytokine and as an extremely powerful 
macrophage-stimulating factor. HMGB1 acts directly by binding to the cell membrane 
inducing signaling and chemotaxis, having a chemokine-like function (Yang et al., 2001), 
and further acting indirectly by up-regulating the expression and secretion of pro-
inflammatory cytokines. This makes extracellular HMGB1 a powerful chemotactic and 
immunoregulatory protein, which promotes an effective inflammatory immune response. 
For HMGB1 the transduction of the receptor signal occurs in part through RAGE 
(Receptor for Advanced Glycation End-products), that is expressed on monocytes and 
macrophages, neurons, endothelial cells, and smooth muscle cells. Released HMGB1 
has been identified as one of the ligands binding to the RAGE receptor. This receptor is 
expressed at a high level mainly in endothelial cells, in vascular smooth muscle cells, in 
monocytes and monophages and in mononuclear phagocytes. Recognition involves the 
C-terminal of HMGB1. The interaction of HMGB1 and RAGE triggers a sustained period 
of cellular activation mediated by RAGE up-regulation and receptor-dependent 
signaling. In particular, the interaction of HMGB1 and RAGE activates several 
intracellular signal transduction pathways, including mitogen-activated protein kinases 
(MAPKs), Cdc-42, p21ras, Rac and the nuclear translocation factor kB (NF-kB), the 
transcription factor classically linked to inflammatory processes (Schmidt et al., 2001). 
According to several experimental evidences, released HMGB1 may also interact with 
the receptors belonging to the family of the Toll-like receptors (TLR), e.g. with the 
subclasses TLR2, TLR4, TLR7, TLR8 or/and TLR9. 
Furthermore, HMGB1 may also interact with the functional N-terminal lectin-like domain 
(D1) of thrombomodulin. Due to the ability of the functional D1 domain of 
thrombomodulin to intercept and bind circulating HMGB1, the interaction of the HMGB1 
with the RAGE receptors and the Toll-like receptors is prevented. 
When released in vivo, HMGB1 is an extremely powerful cytokine and a powerful   
macrophage-stimulating factor and activates in vitro a cascade of multiple 
proinflammatory cytokines (TNF, IL-1[, IL-1], IL-1Ra, IL-6, IL-8, MIP-1[ and MIP-1])
from human macrophages. 
HMGB1 is a late-acting cytokine, appearing in the extracellular milieu with a peak 
around 10 hours after the initial response of macrophages to pro-inflammatory 
stimulation. Knowledge of the role that HMGB1 plays as a cytokine is important for 
understanding regulation of delayed innate immune responses, downstream cytokine 
cascades, and constitutes the basis for targeting treatment strategies towards these 
processes. A window of clinically relevant opportunities allowing rescue from lethal 
sepsis comes from the delayed but effective treatment with HMGB1 blockade up to 1 
day after induction of experimental sepsis. When added to macrophage cultures, 
HMGB1 activates the release of other cytokines and stimulates the autocrine production 
of the same HMGB1 and RAGE. Furthermore, when released into the extracellular 
milieu, HMGB1 causes systemic inflammatory responses including acute lung injury, 
epithelial barrier dysfunction, and death. It was also observed that passive immunization 
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with anti-HMGB1 antibodies confers significant protection against lethality induced by 
LPS administration and sepsis caused by cecal perforation in mice. Moreover, High 
Mobility group Box 1 protein mediates endotoxin lethality, arthritis induction, activation of 
macrophages, smooth muscle cell chemotaxis, and epithelial cell barrier dysfunction. 
Its observed in vitro pro-inflammatory effects and correlation between circulating 
HMGB1 levels and the development of the pathogenic sequence of systemic 
inflammation in vivo indicate that therapeutically targeting HMGB1 should be of relevant 
clinical value, suggesting novel therapeutic approaches by a “late” administration of 
antagonists/inhibitors of the extracellular activities of HMGB1. 
 
1.1.6 HMGB1 recognition of TLR2, TLR4 and RAGE receptors. 
 
HMGB1 potentially activates multiple membrane receptors like RAGE, TLR2, and 
possibly TLR4. RAGE (Receptor for Advanced Glycation End Products) is a multiligand 
member of the immunoglobulin superfamily of cell surface molecules that interacts with 
distinct molecules implicated in inflammation. RAGE stucture consists of three 
immunoglobulin-like regions, one "V"-type region (containing 9 ]-strands connected by 
several loops) followed by two "C"-type domains (containing 7, or more rarely 8, ]-
strands connected by loops in a manner different from the case of  "V"-type domain)15.
Figure 5: Representation of RAGE structure. 
 
15 Understanding RAGE, the receptor for advanced glycation end products; J Mol Med (2005) 83: 876–886 
Angelika Bierhaus . et al.  
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RAGE contains a single transmembrane spanning domain and a 43 amino acid cytosolic 
tail. Structure-function studies suggested that V-domain is important for ligand binding, 
while that the cytosolic tail is essential for RAGE-mediated intracellular signalling. 
HMGB1-RAGE interaction activates MAP kinases pathways, and subsequently causes 
the nuclear translocation of NF-bB, a central regulator of inflammatory responses. 
Inhibition of HMGB1-RAGE interaction suppressed activation of several MAP kinases 
and decreased growth of metastases in vivo16.
Other HMGB1 receptors include Toll-like Receptor 2 (TLR2) and TLR4. Toll-like receptor 
(TLR) family members are transmembrane proteins having the function to activate 
immune responses by recognising molecular structures found in a variety of microbial 
pathogens. Some experimental evidences indicate that TLR2 leads to increased 
secretion of TNF-[ (cytokine inducine HMGB1 release), IL-6, IL-12, and MIP-2 
proinflammatory cytokines. 
Activation of TLR2 and TLR4 by HMGB1 causes recruitment of IL-1 receptor associated 
kinase (IRAK) and MyD88, which subsequently activates the MAP kinases pathway and 
then NF-bB translocation17 (ref). 
 
1.1.7 Strategies for blocking HMGB1 chemokine-protein. 
 
Several strategies were explored to block HMGB1 extracellular chemokine-protein. 
Among the many approaches it is useful to remember the administration of antibodies 
against HMGB1, of antibodies to RAGE, of soluble RAGE (sRAGE), of HMGB1 
fragments (HMGB1 A Box) and of ethyl pyruvate (Czura et al., 2003; Lotze et al., 2003). 
The passive immunization of mice by using HMGB1-neutralizing antibodies conferred a 
highly significant and lasting protection against lethal doses of endotoxin, even when the 
first doses of antibodies were given after the TNF peak had passed, and suggested that 
an effective treatment approach to potentially lethal sepsis resides in antagonizing 
HMGB1 activity late in the clinical course. 
Another possibility is the administration of antibodies against the HMGB1 Box B, or its 
20 amino acid relevant core which signals through RAGE18. Furthermore, HMGB1 Box 
A, one of the two DNA-binding domains in HMGB1, has been identified as a specific 
antagonist of HMGB1: highly purified recombinant Box A protected mice from lethal 
experimental sepsis even when initial treatment was delayed for 24 hours after 
pathology induction, further suggesting that HMGB1 antagonists may be administered 
successfully in a clinically relevant window wider than that one used for other known 
cytokines. Box A domain of HMGB1 competitively displaces the saturable binding of 
HMGB1 to macrophages, specifically antagonizing HMGB1 activities. As already seen 
for the protective activity of anti-HMGB1 antibodies, the administration of the Box A 
rescues mice from sepsis even when treatment initiated as late as 24 hours after 
surgical induction of sepsis. Moreover, saturation of circulating HMGB1 by the 
 
16 Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.Taguchi A, Blood 
DC, del Toro G, et al. Nature. 2000;405:354-360 
17 The Cytokine Activity of HMGB1 - Extracellular Escape of the Nuclear Protein Nian-Kang Sun, PhD; 
Chuck C.-K. Chao Chang Gung Medical Journal REVIEW ARTICLE Vol. 28 No. 10 October 2005 673 
18 HMGB1 as a cytokine and therapeutic target; Yang H.1; Wang H.1; Czura C.J.1; Tracey K.J.; Journal of 
Endotoxin Research, Volume 8, Number 6, December 2002, pp. 469-472(4)  
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administration of sRAGE blocks its activities mediated by cellular RAGE. The same 
result can be also obtained by inhibiting RAGE itself by the administration of anti-RAGE 
antibodies. 
Finally, a similar protective response late in the course of sepsis was obtained by 
administering ethy pyruvate, a stable lipophilic molecule and relatively non-toxic food 
additive, that attenuates the systemic inflammation of ischemia/reperfusion tissue injury 
and lethal hemorrhagic shock. Among its positive effects Ethyl-pyruvate inhibited 
HMGB1 and TNF release in vitro from endotoxin-stimulated murine macrophages, while 
in vivo protected mice from peritonitis-induced lethal sepsis. 
However these therapeutical approaches present some problems: for example is difficult 
to obtain good quantities of pure Box A protein (even by recombinant approach) due to 
its characteristics; anti HMGB1 antibodies can recognise differently HMGB1 produced 
by different cells of the same organism as reported in literature in an example where 
anti-HMGB1 antibodies in serum did not recognize HMGB1 in neutrophils while they 
recognised HMGB1 produced by lymphocytes19. Limits for the use of ethyl piruvate 
come from the absence of informations about its action mechanism; furthermore, ethyl 
piruvate activity is also lower than that showed by anti HMGB1 antibodies20.
Thus, a new approach was explored in this thesis based on the use of DNA or DNA like 
molecules effording to a significative contribute in the field of anti HMGB1 therapeutics 
as described in the next sections. 
 
19 Conformational Difference in HMGB1 Proteins of Human Neutrophils and Lymphocytes Revealed by 
Epitope Mapping of a Monoclonal Antibody; Ichiaki Ito, Nobuyoshi Mitsuoka, Junko Sobajima, Hiroko 
Uesugi, Shoichi Ozaki, Kazuhiko Ohya and Michiteru Yoshida. J. Biochem. 136, 155–162 (2004). 
20 Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation PNAS 
Luis Ulloa, Mahendar Ochani, Huan Yang, Mahira Tanovic, Daniel Halperin, Runkuan Yang, Christopher 
J. Czura, Mitchell P. Fink and Kevin J. Tracey| September 17, 2002 | vol. 99 | no. 19 | 12351-12356  
22 
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1.2 DNA duplexes as HMGB1 inhibitors. 
 
1.2.1 The idea: to use the nuclear ligand for extracellulary inhibiting the activity of 
HMGB1 protein. 
 
As previously described in this thesis HMGB1 binds to DNA molecules in the nucleus 
allowing in this way for the binding of transcriptional factors to DNA. 
On the other hand HMGB1 extracellularly binds to RAGE, TLR2 and TLR4 receptors 
(see 1.2.7 section) activating several inflammatory processes. 
The strategy presented in this thesis for inhibiting HMGB1 is based on a ligand 
exchange. In other words, the idea was to use the HMGB1 nuclear ligand outside its 
natural location to antagonise the extracellular ligands to avoid the inflammatory effects 
of HMGB1.  
Consequently some DNA structures were firstly considered for this anti-HMGB1 
strategy. In an improved approach chimeric molecules composed by PNA and DNA 
molecules were then realised to take advantage of the interesting enzymatic stability 
properties of PNA-DNA chimeras. 
 
Figure 6: Ligand exchange to antagonize RAGE-HMGB1 interaction and the consequent 
proinflammatory effects. 
 
1.2.2 Bent DNAs Design and Modelling 
 
When HMGB1 binds to DNA, it causes bending of linear DNA structures. Furnishing to 
HMGB1 a DNA already in the conformation suitable for the binding would decrease the 
activation energy for the binding process. Thus, the approach described in this thesis 
was based on the hypothesis that bent DNA duplexes could have the right 
conformational requirements for binding HMGB1 at high affinity. 
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Five DNA strands were synthesised having the following sequences: 
 
24-mer  3’ OH-GTTGCATTGAAAAAATTTCTTAGG-5’OH       6A 
18-mer 5’OH-CAACGTAAC - - - - - - AAAGAATCC-3’OH 
 
22-mer  3’OH-GTTGCATTGAAAATTTCTTAGG-5’OH   4A 
18-mer 5’OH-CAACGTAAC - - - -AAAGAATCC-3’OH 
 
20-mer 3’OH-GTTGCATTGAATTTCTTAGG-5’OH    2A 
18-mer 5’OH-CAACGTAAC - - AAAGAATCC-3’OH  
 
18’-mer 3’OH-GTTGCATTGTTTCTTAGG-5’OH    0A 
18-mer 5’OH-CAACGTAACAAAGAATCC-3’OH  
 
The sequences of these DNA molecules were derived by a sequence already published 
in a paper showing the interaction between the Drosophyla HMGB1 homologous and a 
DNA duplex containing a 2 adenines asymmetric insertion21.
T AG
AT
AT
C
A
AA
A
G
G
CTA
AT T
AG
AT
AT
C
A
A
A
G
G
CTA
AT T AG
AT
AT
C
AA
A
G
G
CTA
AT
TAA
A
A
G
T
T A
A T
C G
5'
3'
3' 5'
6A 4A 2A 
bent DNA duplexes
C
T A
T A
CG
C
G C
TA
A
G
T
T A
A T
C G
5'
3'
3' 5'
C
T A
T A
CG
C
G C
A TA
G
T
T A
A T
C G
5'
3'
3' 5'
C
T A
T A
CG
C
G C
Sequences were checked for the absence of competitor target sequences in the human 
genome by BLAST in the EMBL sequence database22 and for the lack of self-
complementarity by the software MFOLD23.
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Afterwards, three bent structures (6A, 4A and 2A) were realised by using DNA duplexes 
carrying in the middle some unpaired nucleotide residues (six, four and two adenines 
respectively). In this way, it was possible to obtain by solid phase synthesis some 
structures presenting an extruding loop formed by the unpaired monomers.  
In order to elucidate the role of the asymmetric bulge in inducing the DNA bending, 
modelling studies were performed on the three DNA duplexes by using as starting data 
the coordinates available from the following PDB files: 
- 1E7J, corresponding to a Box B found in HMGD protein, a HMGB1 homologous 
present in Drosophyla, in complex with a DNA molecule similar to those used in 
this work (carrying two adenines in the asymmetrical bulge); 
- 1CKT, corresponding to HMGB1 Box A in complex with a DNA bent by cisplatin; 
- 1QSK, corresponding to a DNA duplex carrying an asymmetrical bulge containing 
5 adenine residues. 
- 1HME, corresponding to free Box B of HMGB1 
These modelling studies, and particularly the comparison with the structural data from 
1QSK file, showed that the asymmetrical bulge can bend the DNA duplexes designed in 
this work even in absence of HMGB1. In other words, bending is not an effect due to 
HMGB1 binding only, but is rather an intrinsic property of the used DNA duplexes, due 
to the unpaired region present in the middle of them. 
Three-dimensional models for the complexes of HMGB1 with DNAs containing different 
asymmetric insertions/deletions, were obtained by homology on the basis of the 1E7J, 
1HME and 1QSK PDB files. In particular, we focused on the three DNA duplexes 
containing an insertion of 2, 4 or 6 adenines, called duplex 2A, 4A and 6A respectively.  
Models of stable DNA structures were obtained only for 2A and 4A duplexes, since it 
was not possible to accommodate in a defined structure all the adenines in the 6A 
duplex. The 2A duplex presents a continuous stacking between the 2 adenines of the 
insertion and the T preceding the bulge preventing H-bond formation of an A-T base 
pair, as shown in the picture below. Immediately after the adenines, there is a sharp 
bent of the DNA duplex, with stacking interruption and H-bond conservation between 
subsequent G-C base pair. The 4A duplex presents a continuous stacking between the 
first 3 adenines of the insertion. After the third adenine, there is a sharp bent, with 
stacking interruption. In this case the G-C base pair hydrogen bonds are lost. In 
summary we expected a major stability for 2A duplex because the stacking contribute 
per adenine is bigger than that present in 4A; in addition, a GC (3 H-bonds) base pair is 
retained in 2A instead of an AT (2 H-bonds). On the other hand, in 4A an AT base pair is 
retained a more significant GC interaction is lost. 
No stable, stacked structure could accommodate a 6 adenine bulge, suggesting a lower 
stability for the 6A duplex. 
 
21 HMG-D complexed to a bulge DNA: An NMR model; Rachel Cerdan,1, Dominique Payet,2, Ji-Chun 
Yang, Andrew A. Travers and David Neuhaus; Protein Science (2001), 10:504-518. 
22 P. Hingamp, A. E. van den Broek, G. Stoesser, W. Baker, Mol Biotechnol 1999, 12, 255. 
23 E. A. Skripkin, A. B. Jacobson, J Mol Biol 1993, 233, 245. 
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Figure 7: Modelling studies predicted the best stability for 2A DNA duplex. Bulge bases 
in the PDB models are purple. In the schematic representation, in grey are evidenced 
the bases involved in the stacking. Bases which do not participate to Watson-Crick 
hydrogen bond formation are red. White letters indicate bases that retain the hydrogen 
bond. 
 
1.2.3 DNA Synthesis, purification and characterisation 
 
Oligonucleotide synthesis was performed on an ABI/Perceptive Biosystems Expedite 
model 8909 Synthesizer that allows to synthesise not only DNA/RNA oligomers (0.02 
µmol to 15 µmol scale) but also PNA (2 to 8 µmol scale) and other DNA analogues. 
Synthesis was accomplished on controlled pore glass supports in a 3' to 5' direction. 
Synthesis scale of the DNA oligomers was 1 micromole using standard protocols like 
that reported as an example below: 
 
2A duplex           4A duplex 
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DNA synthesis was based on the ]-Cyanoethyl Phosphoramidite Chemistry  and 
commercial phosphoramidites used in this thesis are successively shown. 
 
ABI / Perceptive Biosystems Expedite model 8909 
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The exocyclic amines of 2’-deoxyadenosine (dA), 2’-deoxycytidine (dC) are protected by 
benzoyl (bz) groups at the N4 and N6 positions, respectively, while the 2’ 
deoxyguanosine (dG) is protected at the N2 position by an isobutyryl (ibu) group. The 
phosphoramidite monomers are also protected at the the 5’-hydroxyl position with a 
DMT group and the 3’-phosphite brings ]-cyanoethyl and diisopropylamine groups. 
 
DNA synthesis followed the standard cycle that begins with the 3'-hydroxyl nucleoside 
attached to a solid CPG (Controlled-Pore Glass) support through a long spacer linker. 
The first step in the synthesis is the removal of the dimethoxytrityl (DMT) group with TCA 
(detritylation) to free the 5'-hydroxyl for the coupling reaction. As the DNA bases are 
acid-labile, the detritylation step must only be as long as is necessary to ensure 
complete detritylation. After detritylation the next protected phosphoramidite is delivered 
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to the reaction column. Tetrazole is used to activate the phosphoramidite. The two 
reagents are premixed just prior to delivery to the reaction column. Tetrazole, acting as a 
weak acid,  protonates the tertiary nitrogen group of the phosphoramidite and the 
diisopropylamine moiety, as a good leaving group, is displaced during the successive 
nucleophilic attack of 5’-hydroxyl group on the 3’-phosphorous the incoming activated 
monomer. To have a totally hydroxyl-free environment in the column dry acetonitrile is 
used as the general solvent, and all the reagents and solvents used are anhydrous. 
Under these conditions the coupling efficiencies are very high, thereby permitting 
synthesis of long oligonucleotides. Unreacted 5’-hydroxyl groups (1-2%) are capped by 
acetylation to avoid further elongation in the the next cycles. This is achieved using 
acetic anhydride and N-mehtyllimidazole as activated acetylating agent. The 
internucleotide linkage is then converted from the less stable phosphite to the 
phosphotriester in the oxidation step. Iodine is used as the oxidizing agent and water as 
the oxygen donor. After oxidation, the DMT group is removed with trichloroacetic acid 
and the cycle is repeated until chain elongation is complete. Coupling efficiency has 
been estimated spectrophotometrically by measuring DMT cation released during the 
detrytilation step.  An example of trytil monitoring during the synthesis is shown in figure 
8
Fig.8: On-line trytil monitoring of DNA with 6 adenines in the bulge (24-mer). 
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The oligos is then cleaved from the solid support with concentrated ammonium 
hydroxide at 65 °C. Ammonia treatment also deprotects the phosphorus by ]-elimination 
of the cyanoethyl group. After cleavage/deprotection, the resulting crude mixture 
contains the oligonucleotide, the truncated failure sequences with free 5’-hydroxyl ends, 
by-products of deprotection (benzamide, isobutyramide, acrylonitrile, and acetamide), 
and silicates from hydrolysis of the glass support. Anion exchange HPLC separate 
oligonucleotides by length. Normally the product is longer than the failure sequences.  
Chromatographic separation was performed using a Waters 600 Controller, equipped 
with the diode array detector Waters 996 and with Millennium software. A Nucleogel 
SAX column  (Machery Nagel SAX 1000-8 4.6x50 mm) was used for this procedure. 
Solvent A was made up of 20 mM K2HPO4, pH 7.0, 20% CH3CN and solvent B of 1 M 
KCl in 20 mM K2HPO4, pH 7.0, 20% CH3CN. Oligos were separated by using a linear 
gradient of B in A at a flow rate of 1 ml min–1. Detection was performed at 260 nm. 
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24-mer (6 adenines): from 20 % to 75 % of B in A in 35 min 
 
22-mer (4 adenines): from 25 % to 75 % of B in A in 25 min 
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20-mer (2 adenines): from 25 % to 75 % of B in A in 30 min 
 
18-mer: from 25 % to 75 % of B in A in 35 min 
 
After purification DNA oligomers were liophylised, dissolved in a known amount of milliQ 
water and quantified by UV measurements (T= 80 °C, Absorbance value at d=260 nm). 
The epsilon used for the quantification of the oligos are calculated using molar extinction 
coefficients as follows: A, 15.4; T, 8.8; G, 11.7; C, 7.3 mM-1 and are: 
24 mer, A8C2G5T9: 260=268900 M-1 
22 mer, A6C2G5T9: 260=244700 M-1 
20 mer, A4C2G5T9: 260=213900 M-1 
18’ mer, A2C2G5T9: 260=169600 M-1 
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18 mer, A9C5G2T2: 260=216100 M-1 
UV quantification of the oligos provided the following values: 
24 mer = 310 nmol (2.30 mg, 31 % yield); 
22 mer = 320 nmol (2.17 mg, 32 % yield); 
20 mer = 340 nmol (2.09 mg, 34 % yield); 
18’mer = 344 nmol (1.90 mg, 34% yield); 
18 mer = 345 nmol (1.89 mg,35 % yield). 
All DNA oligomers were characterised by MALDI-TOF MS performed on a PerSeptive 
Biosystems Voyager-DE MALDI-TOF mass spectrometer using 3-hydroxypicolinic acid 
/ammonium citrate =8/1 in water : acetonitrile= 1:1. 
24 mer: Observed Mass  [M-H]- = 7403.7; Calculated Mass [M-H]- = 7404.9; 
22 mer: Observed Mass  [M-H]- = 6778.9; Calculated Mass [M-H]- = 6778.5; 
20 mer: Observed Mass  [M-H]- = 6151.9; Calculated Mass [M-H]- = 6152.1; 
18’mer: Observed Mass  [M-H]- = 5527.0; Calculated Mass [M-H]- = 5525.6; 
18 mer: Observed Mass  [M-H]- = 5470.4; Calculated Mass [M-H]- = 5468.7. 
 
1.2.4 Stability studies of bent DNA duplexes 
 
Annealing of DNA. Equimolar amounts of complementary oligonucleotide strands were 
combined and dissolved in buffer (5 mM phosphate, 1mM MgSO4, pH 7) to achieve DNA 
concentration of 2 µM . The solution was heated at 85 °C (10 min) and then allowed to 
cool slowly to room temperature.  
The different bent DNA duplexes had to be tested for their ability to bind HMGB1 in 
order to find the best candidate to be used as DNA (or analogue)- based therapheutical 
agent against HMGB1. Stability of the free DNA duplexes was studied to find any 
dependence on the bulge length. Thermal stabilities for the four DNA duplexes were 
determined by Circular Dichroism (CD) experiments. All CD spectra were collected on a 
Jasco J710 spectropolarimeter equipped with a NesLab RTE111 thermal controller 
unity, using a quartz cylindrical cuvette with a 1-cm path length (Jasco). CD melting 
curves were recorded by following the decrease in ellipticity at 278 nm with a heating 
rate of 1 °C/min. 
The Tm for the duplex 2A, 4A, 6A and 0A are reported in the following table: 
 
Tm (°C) 
0A 48.26 ± 0.10 
2A 36.99 ± 0.04 
4A 34.40 ± 0.03 
6A 31.40 ± 0.04 
The first important consequence of the presence of the bulge is immediately evident by 
comparing 0A to all the other duplexes: the presence of the bulge destabilizes the 
duplex. This is an effect which is remarked by a Tm difference between 0A and the other 
duplexes ranging from 11 to 17 degrees. The effect is consistent with the data in the 
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literature24, showing that even a single-base bulge has a profound destabilizing effect on 
the duplex. Furthermore, as predicted by the modelling, stability decreases as the 
number of adenine residues in the bulge increases. The most stable bent DNA duplex 
was that carrying two adenines (i.e. 2A, with a melting temperature of 37.0 °C). Thus, 
the 2A duplex adopts the most stable folding, followed by the 4A and by the 6A 
duplexes, respectively. 
CD studies was also used to have information on the conformation and in particular on 
the amount of stacking for each bent duplex. For this reason, we recorded CD spectra of 
the DNA duplexes 0A, 2A, 4A and 6A at the same concentration at 15 °C. CD spectrum 
obtained for 2A (2µM, 15 °C) is reported below as an example. 
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In all cases the CD spectrum confirmed the formation of the DNA duplex with an 
adenine loop extruding from the double helix. After transformation in the corresponding 
molar ellipticity spectra, the spectrum of 0A was subtracted from each bent duplex 
spectrum to obtain the CD contribute due only to the loop present in every bent 
structure. In fact this operation, assuming that the two arms flanking the central bulge 
have substantially the same structure in all bent duplexes (B-form DNA), eliminates the 
contributions coming from all the bases, except for the adenines in the central bulge, 
and gives the “bulge spectrum” for each bent duplex. By dividing the “bulge spectra” for 
the number n of adenines composing the corresponding bulge, it was obtained the 
average spectrum for the bulge adenines contained in each of the studied bent 
duplexes, as reported in figure 9 
 
24 Influence of neighboring base pairs on the stability of single base bulges and base pairs in a DNA fragment. Ke SH, 
Wartell RM; Biochemistry. 1995 Apr 11;34(14):4593-600.  
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Figure 9: CD “bulge spectra” for 2A, 4A and 6A DNA duplexes. 
 
While the molar ellipticity spectra of the adenines in the 4A and 6A duplexes are very 
similar in intensity and shape, the 2A spectrum is very peculiar, with a very intense CD 
band at 205 nm due to the stacking contribute of adenines. This observation supports 
the modelling studies, described before, that evidenced a bigger stacking ability for 2A 
duplex. 
 
1.2.5 Stability studies of HMGB1-bent DNA complexes 
 
Once thermal stability was found for free DNA duplexes, complexes with HMGB1 were 
studied. Circular dichroism (CD) spectra were obtained by using special “Tandem Mix” 
cells (Suprasil quartz, Hellma, showed below) which minimize errors relative to the 
obtainment of the exact concentration of both DNA and protein before and after the 
complex formation. This is particularly important when one studies by CD very little 
differences due to the interactions. 
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Light Path: 2 x 4.375 mm 
Height: 46 mm 
Width:  12.5 mm 
Depth: 12.5 mm 
Inner 
Dimensions:  
Width:  9.5 mm 
Base 
Thickness: 
 
1.5 mm 
The CD spectrum obtained from the tandem mix cell before mixing corresponds to the 
sum of the spectrum of free HMG box B protein domain and free DNA duplex. The 
protein region of the spectrum (200-230 nm) changes significantly after the components 
are mixed, while the CD spectrum region where only DNA contributes remains almost 
unchanged, reflecting little conformational changes in the bent DNA (see Fig 10).  
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Figure 10 CD spectra of HMGB1-B Box (21 µM) and 2A (2 µM) obtained in a tandem 
mixing cell at 15 °C: sum spectrum (free HMG box-B domain in cell 1 and free DNA in 
cell 2 before mixing, blue line), complex spectrum (after mixing of the two cells, red line).  
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Figure 11: CD spectra of HMGB1-B Box (21 µM) / 4A (2 µM) complex (red line) and sum 
(blue line) at 15 °C.  
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Figure 12: CD spectra of HMGB1-B Box (21 µM) / 6A (2 µM) complex (red line) and sum 
(blue line) at 15 °C.  
 
“Difference spectra” were obtained in all three cases by subtracting the CD spectrum of 
the SUM from the complex spectrum, and confirmed the effectiveness of the HMGB1 B 
Box-DNA binding. The greater “difference spectrum” comes from the 6A duplex. 
Assuming that the CD contribution of the protein is the same for every bent-duplex, the 
increasing induced deformation from 2A to the 6A by the protein indicates that a bigger 
DNA structure deformation is needed for binding in the case of the 6A duplex. In other 
words, the binding of the protein to the 6A duplex requires a greater reorganization of 
the duplex structure, thus destabilizing the resulting complex as compared to the 4A and 
2A respectively.  
 
Figure 13: CD “difference spectrum” for 2A, 4A and 6A DNA duplexes. 
 
Thermal stability of the complexes HMGB/bent DNA duplex was obtained by CD melting 
curves (from 4 to 60 °C) and was compared with DNA thermal stability in the free form 
(Figure 14). The most stable bent DNA duplex in complex with HMGB1 was 2A with a 
melting temperature of 40 °C. The energy differences (gTm) between the bound and 
unbound DNA duplexes is very similar in all cases. This means that the total stabilisation 
due to the formation of the protein/DNA complex is comparable in all cases, giving a 
stability trend for the complexes which closely matches the trend observed for free DNA 
duplexes. Thus, the protein binds bent DNAs always in the same manner, and the 
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stability of the resulting complex is strongly related to the stability of the corresponding 
DNA duplex. The lowest complex stability is observed in the case of 6A where, as 
evidenced also from the CD “difference spectra” (Fig…), the binding of the protein to the 
6A duplex requires a greater reorganization of the duplex structure, thus destabilizing 
the resulting complex as compared to the 4A and 2A respectively. This deformation is 
paid energetically in terms of the stability of the resulting complex, explaining the 
decreasing thermal stability trend observed for the protein/DNA complexes as the 
number of adenines into the central bulge increases. 
 
Figure 14: Normalised CD melting curves between 0 ad 1 for DNA duplexes in complex 
to HMGB1 and Tm table of  bent duplexes, free and in complex to HMGB1. 
 
Affinity of HMGB1 for the most stable duplex, the 2A,was obtained performing CD 
titration experiments in H2O. In a solution of 1.15 µM DNA duplex the concentration of 
HMGB1 was increased from 0 to 1 iM. From CD spectra collection a Kd of about 20 10-9 
M was determined, according to an equation reported in literature25. Titration profiles 
were obtained reporting the CD variation, normalised between 0 and 1, at d= 221nm, 
where both HMGB1 and DNA contribute, and 278 nm (only DNA influence) versus 
HMGB1 concentration (Figure 15). Binding isotherms are almost identical in both the 
cases and this suggests that HMGB1 protein does not modify significantly its structures 
when binds to DNA.  
 
25 C. Isernia, E. Bucci, M. Leone, L. Zaccaro, P. Di Lello, G. Digilio, S. Esposito, M. Saviano, B. Di Blasio, 
C. Pedone, P. V. Pedone, R. Fattorusso, Chembiochem 2003, 4, 171 
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Figure 15: CD titration of 2A DNA duplex with HMGB1 in water at 15 °C (protein/DNA 
ratio  1). 
 
In conclusion, the most stable HMGB1-DNA complex is obtained in the case of the loop 
with 2 adenine residues. Consequently our attention was focused on the obtainment of 
the more enzymatically stable PNA-DNA chimeric duplex presenting an asymmetrical 
bulge of two adenines. 
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1.3 PNA/DNA chimeras for HMGB1 inhibition. 
 
1.3.1 Introduction  
 
By taking advantage of the synthetic procedures optimised in this thesis and described 
in the following sections it was possible to obtain PNA chimeric molecules in good 
amount and this allowed for their use in several in cell and in vivo experiments that 
furnished the interesting results reported in this work.  
A chimeric duplex called 2A was realised with a loop of two adenines. Two chimeric 
strands carrying the PNA moiety at 3’ end were synthesised (5’DNA-3’PNA). These kind 
of molecules are expected to be more resistant to enzymatic degradation than the 
corresponding 5’DNA-3’PNA, since in serum 3’ exonucleases are more abundant than 5’ 
exonucleases22. The nucleobase sequence for the two strands is below reported (the 
first three monomers at 3’ terminus were PNA monomers and are indicated by small 
letters in both the chimeric strands): 
 
20-mer COOH-ctt*GCATTGAATTTCTTAGG-5’OH   Chim 2A 
18-mer 5’OH-GAACGTAAC - - AAAGAA*tcc-COOH 
 
The same positive characteristics in the interaction with HMGB1 already found for 2A 
were expected also in the case of Chim 2A. However a further improvement in the in 
serum stability was also expected for Chim 2A as a consequence of the presence of 
PNA moieties in the nucleotidic strands. By using these strands, a duplex 
chimera:chimera was obtained. UV spectroscopy and Circular Dichroism experiments 
were performed in order to verify the duplex formation and to determine the melting 
temperature.  
Subsequently, the in serum resistance for this chimeric duplex was studied (see section 
1.3.9). Other experiments were carried in cells to verify the ability of the chimeric 
complex to inhibit the activities of HMGB1 (see section 1.3.10). Finally the chimeric 
duplex was used in multiple in vivo experiments, in a mouse inflammation model (see 
section 1.3.10). 
 
1.3.2 PNAs: useful characteristics and limits 
 
Peptide nucleic acids (PNAs) are among the most powerful oligonucleotides analogues, 
with a N-(2-amino-ethyl)-glycine unit replacing the sugar-phosphate backbone1-4. PNAs 
show strong and sequence specific hybridisation to complementary DNA and RNA5 as 
well as to double stranded DNA by triplex formation6. This type of DNA mimic is not 
degraded by nucleases and proteases7 and present both good antisense and antigene 
activity8-13.
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Figure 16: PNAs are DNA analogues with a pseudopeptidic backbone. 
 
Although pure PNAs have truly remarkable binding properties, their handling during 
work-up, analysis and purification is often difficult because of their tendency to 
aggregate. Moreover, due to their neutral character the water solubility is limited2.
Afterwards, since PNA binding to complementary oligonucleotides induces structural 
conformational variations with respect to natural complexes, proteins do not recognise 
PNA-oligonucletides complexes. 
 
43 
Figure 17: Structures of RNA-RNA duplex and PNA-RNA duplex: an example of 
conformational variation due to PNAs27.
1.3.3 PNA-DNA chimeras  
 
The synthesis of chimeric molecules composed of PNA and DNA is a possible approach 
to address PNA problems, and has been shown to improve the cellular up-take of 
PNAs.14 PNA/DNA chimeras might combine the high binding efficiency and specificity of 
PNA, with the ability of DNA to interact with proteins, for examples with RNasi H in 
antisense applications,15 or might function as a primer for DNA polymerases.15 
Preliminary experiments in cell cultures have shown that PNA/DNA chimeras used as 
antisense oligomers are capable of inhibiting the expression of specific target genes.16 
Figure 18: 5’DNA-3’PNA chimeric duplex 
 
Furthermore, PNA parts attached to 3' and 5' ends of a DNA in a PNA/DNA chimera 
stabilize the molecule against degradation by 3'- and 5'-exonucleases, which are the 
main classes of oligonucleotide-degrading enzymes found in serum. In summary, 
PNA/DNA chimeras are taken up by cells, are largely nuclease-resistant, and have an 
excellent binding affinity to complementary oligos without having PNA drawbacks, so 
that they fulfil the basic requirements for antisense oligomers to be biologically active. 
 
1.3.4 Problematic aspects in the synthesis of PNA-DNA chimeras  
 
The step-wise “on-line” solid-phase synthesis with suitably protected monomeric building 
blocks has proved to be the most successful and flexible method for the synthesis of 
PNA/DNA chimeras and modified PNA.17-20 Classically the automated synthesis of DNA 
and PNA proceeds in 3' to 5' direction for DNA and pseudo 3' to pseudo 5' for PNA, 
where pseudo 3' corresponds to the COOH terminus while pseudo 5' corresponds to the 
amino terminus of the PNA. 
Commercial Fmoc/Bhoc or Boc/Cbz PNA monomers (where the first abbreviation 
denotes the protecting group on the backbone, while the second one that on the 
nucleobase) are not compatible with DNA synthetic chemistry because the deprotection 
of the amino group on the nucleobases from the Bhoc group (in Fmoc/Bhoc monomers) 
or on the backbone from the Boc group (in the Boc/Cbz monomers) is achieved by TFA 
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treatment, which would cause depurination of the DNA part of the chimera. Moreover, 
use of PNA monomers containing Fmoc group for temporary protection of the amino 
function in the backbone forces to utilize the 5'-DMT-O-methylated phosphoramidite 
instead of the less expensive standard DNA monomers (DMT-CNE- phosphoramidite) 
for the assembly of the DNA part in a chimera of the type PNA-DNA-PNA or 3'DNA-
PNA. Furthermore it was reported that Fmoc protection in PNA backbone gives the 
lowest coupling yields in comparison to other protecting groups, probably because in 
Fmoc-PNA synthesis, where aggregation is frequently a problem, the removal of the 
Fmoc group becomes an issue.21 A milder and more convenient method compatible with 
conditions for DNA synthesis requires utilization of PNA monomers containing the Mmt 
group for the temporary protection of the N-terminus and acyl protecting groups for the 
nucleobases.22-25 
The lypophilic Mmt group improves the solubility of the protected monomers in polar 
organic solvents, such as DMF or CH3CN. The assembly of the DNA part can be carried 
out with commercially available, standard DNA monomers. The temporary protecting 
group Mmt can be removed under mild acidic conditions (3% TCA), and the coupling 
efficiency, which can be determined very easily by measurement of the coloured Mmt 
cation release, is in the order of 95-99%.22-25 The nucleobase protecting groups are 
removed at the end of the synthesis. This highly efficient and flexible strategy allows for 
the automated synthesis of PNA/DNA chimeras using equipment and conditions very 
similar to those employed in standard DNA synthesis. 22-25 
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Figure 19: PNA-DNA-PNA chimera 
 
Two linking monomers are needed to perform an automated solid phase synthesis of 
chimeric molecules of the type PNA-DNA-PNA.14 The first one to pass from DNA to 
PNA, forming an amide bond at the 5' end of DNA, is already commercially available (5'-
amino-5'-deoxythymidine phosphoramidite) (linker 1, Fig. 1). To connect the PNA part of 
the chimera to the DNA a 2-(hydroxyethylglycine) unit may be used to form a 
phosphodiester bond with the 3' end of the DNA (linker 2, Fig. 1). In particular, Mmt-O-
protected nucleobase-derivatised hydroxyethylglycine is useful to this aim. Synthetic 
routes to Mmt PNA monomers22-25 as well as to Mmt PNA-3'DNA linkers25, 26 for the 
synthesis of PNA/DNA chimeras, have been previously reported in literature. However, 
the synthetic procedures for the obtainment of these useful building blocks and the 
corresponding yields are not yet optimal and further improvements in this regard are 
clearly desirable. 
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In this paper we present a convenient synthesis of Mmt PNA monomers and Mmt PNA-
3'DNA linker which takes advantage of the introduction of the Mmt protecting group in 
the first step. 
 
1.3.5 Synthesis of building blocks for PNA-DNA chimeras  
 
MATERIALS AND METHODS 
 
The following abbreviations are used: 4-methoxybenzoyl (An); benzhydryloxycarbonyl 
(Bhoc); tert-butoxycarbonyl (Boc); benzyloxycarbonyl (Cbz), cyanoethyl (CNE); N,N’-
diisopropylcarbodiimide (DIC); N,N-dimethylformamide (DMF); di-(4-
methoxyphenyl)phenylmethyl (Dmt); 9-fluorenylmethoxycarbonyl (Fmoc); 1-
hydroxybenzotriazole (HOBt); (4-methoxyphenyl)diphenylmethyl (Mmt); 4-
methylmorpholine (NMM); triethylamine (TEA); trifluoroacetic acid (TFA). 
HOBt was purchased from Novabiochem. Solvents for chromatography were from Carlo 
Erba and Lab-Scan while dry solvents and all other reagents were purchased from 
Sigma-Aldrich-Fluka. All reactions were performed in glassware, which had been oven 
dried (120 °C, at least 3h) and then flame-dried under Ar atmosphere prior to use. TLC 
were run on silica gel Macherey-Nagel G-25 UV254 plates, and visualised by UV light and 
by a Ce(SO4)2 or ninhydrin staining solution. Column chromatography was performed 
using silica gel 60 (230-400 mesh). 
 
Apparatus 
 
1H NMR and 13C NMR spectra were recorded on VARIAN UNITY 400 MHz spectrometer 
equipped with a computer SUN ULTRA 5. Chemical shifts (k) are quoted in parts per 
million (ppm), downfield from tetramethylsilane, and all coupling constants (J) are quoted 
in Hz. For the assignments of Mmt 13C NMR signals we have used the convention 
showed below: 
 
MeO
1'
2'
3'
4'
6'
5'
7'
8'
 
MALDI mass spectra were obtained using a Perseptive Biosystems Voyager DE 
spectrometer with a sinapinic acid matrix 
 
Mmt/Acyl protected PNA monomers 
 
46 
For the synthesis of PNA monomers we followed a general strategy relying on the use of 
protected N-(2-amino-ethyl)-glycine (backbone) and protected N1/9-(methyl-carbonyl)-
bases. These moieties were subsequently coupled to give the desired PNA monomers 
(to be used for polymer synthesis). The backbone contains Mmt group as temporary 
protection of the N-terminus and the nucleobases bring an acyl protection on the 
exocyclic NH2.
The Mmt backbone 3 was obtained in two synthetic steps from ethylenediamine 1 with 
an overall yield of 65%, higher than previously obtained (Scheme 1).22 
NH2
NH2 MmtNH NH2
1
MmtNH N
H
O
OMe
overall yield: 65% (2 steps)
2
3
(i) (ii)
Scheme 1. 
 
Since the introduction of the -CH2COOMe group into the ethylenediamine complicates 
the separation of the product from the excess of starting material, we have chosen to 
introduce first the Mmt group and then the carboxymethylene moiety. In particular, the 
ethylenediamine was protected selectively at one of the primary amino group by reaction 
with MmtCl to give compound 2. Crude compound 2 was reacted without purification 
with methylbromoacetate to give 3. The 1H NMR chemical shifts of the backbone 3 were 
in good agreement with those reported in literature.22 The 13C NMR complete 
assignment of 3, never reported before, is reported in the experimental part. 
The synthesis of the desired protected N1/9-(methyl-carbonyl)-bases was accomplished 
according to reported procedures,22 which require first the protection of exocyclic NH2 of 
adenine, cytosine and guanine with An-, t-Bu-Bz- and iBu- groups respectively and then 
the insertion of a methylene carbonyl moiety by alkylation of the protected nucleobases 
with BrCH2COOMe, followed by saponification, under controlled pH conditions, using 
aqueous NaOH and dioxane. Carboxymethylated thymine was easily synthesized 
according to the procedure of Kosynkina et al.27 In the synthesis of the 
carboxymethylated bases (5 and 7, Scheme 2), the yields for the reactions of protected 
cytosine 4 and protected adenine 6 with methyl bromoacetate were of 60% and 82%, 
respectively. We suggest that these improved yields can be attributed to changes in the 
temperature during the addition of the reactants and the use of sodium hydride in 
mineral oil instead of the extremely reactive absolute one. 
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Scheme 2. 
 
The N1/N9-carboxymethylated bases (8, 9, 10, 11, Scheme 3) were attached to the 
backbone under standard coupling conditions using HOBt/DIC/NMM in DMF to give the 
Mmt/Acyl PNA methylester monomers (12, 13, 14, 15, Scheme 3). In the condensation 
step, by optimisation of the reaction and work-up, we got a better yield as compared to 
what previously reported in the case of the coupling reactions between 9 and 10 and the 
backbone 3, obtaining products 13 and 14 with a 96% and 83% yield, respectively. 
Finally, saponification with NBu4OH of the resulting methylesters 12, 13, 14 and 15, 
under controlled pH conditions, gave the desired Mmt/Acyl PNA monomers as tetrabutyl 
ammonium salts in about quantitative yields. 
All the PNA monomers were characterized on the basis of their NMR spectra, which 
were in good agreement with those reported in literature. 
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N-(2-(4-Methoxyphenyl)diphenylmethylaminoethyl)glycine methyl ester 3 (Scheme 1). 
MmtCl (1.02 g, 3.32 mmol, 1 eq), dissolved in 5 ml of pyridine, was added to a stirred 
solution of ethylenediamine 1 (2 ml, 29.9 mmol, 9.0 eq) in 7 ml of dry CH2Cl2, at 0 °C in 
portions over a period of 1 h. After stirring for 2 h, the reaction was quenched by adding 
1 ml of methanol and evaporated to dryness. On TLC there was prevalently one spot at 
Rf= 0.14 (8:2 CH2Cl2/MeOH). Crude compound 2 was extracted by H2O/CH2Cl2 (1% 
TEA) and the dichloromethane extracts were evaporated under reduced pressure, 
redissolved in dry CH2Cl2 and Et3N (3.32 mmol, 462 µl, 1 eq) and directly reacted with 
BrCH2COOMe (336 µl, 3.65 mmol, 1.1 eq) which was added to 2 in portions at 0 °C. 
When the reaction was completed (2 h and 40 min) 20 ml of an aqueous solution of 
NaHCO3 (2%) were added and the mixture was extracted by CH2Cl2 (3 ×15 ml). The 
combined organic phases were dried by MgSO4, evaporated under reduced pressure 
and separated by silica gel chromatography using increasing amounts (15-70%) of 
AcOEt in hexane (1% NEt3) as eluent, giving pure samples of 3 (872 mg, 2.16 mmol, 
65% overall yield) as a yellow oil; Rf= 0.32 (98:2 CH2Cl2/MeOH); H (CDCl3) 2.27 (2 H, t, 
J 6.0, CH2), 2.73 (2 H, t, J 6.0, CH2), 3.35 (2 H, s, CH2CO), 3.72 (3 H, s, COOMe), 3.80 
(3 H, s, Mmt-OMe), 7.50-6.80 (14 H, m, Mmt); C (CDCl3) 43.0 (MmtNHCH2), 59.8 
(CH2CO), 50.5 (CH2NHCH2), 51.7 (COOCH3), 55.2 (Mmt-OCH3), 70.2 (CAr3), 113.1 (C-
7’), 126.1 (C-4’), 127.8 (C-3’), 128.6 (C-2’), 129.8 (C-6’), 138.3 (C-5’), 146.4 (C-1’), 157.8 
(C-8’), 173.1 (COOMe). 
 
1-(Methoxycarbonylmethyl)-N4-(4-tert-butylbenzoyl)-cytosine 5 (Scheme 2). 
 
To a suspension of N4-(4-tert-butylbenzoyl)cytosine (4, 800 mg, 2.95 mmol, 1 eq) in dry 
DMF (10 ml), sodium hydride (148 mg, 3.69 mmol, 1.25 eq, 60% in mineral oil) was 
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added in portions under stirring. After 1 h, methylbromoacetate (339 µl, 3.69 mmol, 1.25 
eq) was added dropwise whilst stirring. After 2 h the reaction was quenched by adding 2 
ml of methanol and removing the solvent in vacuo. The residue was extracted by 
CH2Cl2/water and the organic phases were evaporated in vacuo and crystallised from 
isopropanol to give compound 5 (607 mg, 1.77 mmol) as a white solid in 60% yield. Rf
and 1H NMR spectral data were identical to those reported in literature.22 
N6-(4-Methoxybenzoyl)-9-(methoxycarbonylmethyl)adenine 7 (Scheme 2). 
 
To a suspension of N6-(4-methoxybenzoyl)adenine (6, 800 mg, 2.97 mmol, 1 eq) in dry 
DMF (10 ml), sodium hydride (131 mg, 3.27 mmol, 1.1 eq, 60% in mineral oil) was 
added in portions and the mixture was stirred at room temperature. After 30 min, 
methylbromoacetate (300 µl, 3.27 mmol, 1.1 eq) was added dropwise whilst stirring and 
the mixture was further stirred at room temperature. All the reactants were added at 0 
°C. After 2 h the reaction was quenched by a small amount of CO2 in methanol and the 
resulting solution, concentrated to 1.5 ml, was treated with cold water. The precipitated 
product was filtered off, washed by a small amount of cold water and dried in vacuo to 
give compound 7 (830 mg, 2.43 mmol) as a white solid in 82% yield. Rf and 1H NMR 
spectral data were identical to those reported in literature.22 
N-(2-(4-Methoxyphenyl)diphenylmethylaminoethyl)-N-[(N6-(4-methoxybenzoyl)-adenin-9-
yl)acetyl] glycine methyl ester 13 (Scheme 3). 
To a suspension of N6-(4-methoxybenzoyl)adenine (6, 800 mg, 2.97 mmol, 1 eq) in dry 
DMF (10 ml), sodium hydride (131 mg, 3.27 mmol, 1.1 eq, 60% in mineral oil) was 
added in portions and the mixture was stirred at room temperature. After 30 min, 
methylbromoacetate (300 µl, 3.27 mmol, 1.1 eq) was added dropwise whilst stirring and 
the mixture was further stirred at room temperature. All the reactants were added at 0 
°C. After 2 h the reaction was quenched by a small amount of CO2 in methanol and the 
resulting solution, concentrated to 1.5 ml, was treated with cold water. The precipitated 
product was filtered off, washed by a small amount of cold water and dried in vacuo to 
give compound 7 (830 mg, 2.43 mmol) as a white solid in 82% yield. Rf and 1H NMR 
spectral data were identical to those reported in literature.22 
N-(2-(4-Methoxyphenyl)diphenylmethylaminoethyl)-N-[(N2-(isobutanoyl)-guanin-9-yl) 
acetyl] glycine methyl ester 14 (Scheme 3). 
To a solution of [(N2-(isobutanoyl)-9-(carboxymethyl)guanine (10, 155 mg, 0.556 mmol, 
1 eq) in dry DMF (2 ml), HOBt (83 mg, 0.612 mmol, 1.1 eq) was added followed by NMM 
(122 µl, 1.11 mmol, 2 eq) and a solution of the backbone 3 (289 mg, 0.722 mmol, 1.3 
eq) in 2 ml of dry DMF. Finally, DIC (103 µl, 0.667 mmol, 1.2 eq) was added whilst 
stirring. After 64 h the reaction mixture was quenched by addition of few drops of water 
and was evaporated in vacuo. The residue, dissolved in AcOEt, was washed by water 
and the organic extract, evaporated under reduced pressure, was purified by 
chromatography on a silica gel column eluted with increasing amounts of MeOH in 
CH2Cl2 (1% TEA), to give 305 mg (0.461 mmol, 83%) of 14. Rf and 1H NMR spectral 
data were identical to those reported in literature.22 
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Synthesis of Mmt PNA-3’DNA linker 
 
The Mmt-O-protected, nucleobase-derivatised hydroxyethylglycine is a useful monomer 
to connect the PNA part of a PNA-DNA chimera to the 3’ end of the DNA. The reported 
synthesis of a protected (Dmt) hydroxyethylglycine backbone to be coupled to the 
protected carboxymethylated nucleobases brings to the desired backbone in three 
synthetic steps with an overall yield of 41%.25 We obtained the corresponding Mmt 
backbone with an overall yield of 80% in only two synthetic steps. We have chosen the 
Mmt protection because of its greater stability in comparison to the Dmt, used in 
previous works.25,26 The hydroxyl function of commercially available 2-aminoethanol as 
chlorhydrate salt (16, Scheme 4) was protected by treatment with Mmt-Cl in DMF and 
pyridine to give compound 17. A small amount of crude product 17 was purified to check 
its identity by NMR. The 13C NMR chemical shift value (86.1 ppm) of the quaternary 
carbon C(Ar)3 is diagnostic for a (Ar)3C-O as compared to the chemical shift value of 
(Ar)3C-N, which is around 70 ppm. Compound 17 was monoalkylated using methyl-
bromoacetate in CH2Cl2/TEA to give N-(2-(4-
methoxyphenyl)diphenylmethoxyethyl)glycine methyl ester 18 (Scheme 4). 
 
MmtO NH2
MmtO NH O
OMe
overall yield:  80% (2 steps)
NH2
OH
17
18
16
.HCl
(i) (ii)
 
Scheme 4. 
 
The synthesis of the linker monomers requires the coupling between the protected N-(2-
hydroxyethyl) glycine (backbone 18) and protected N1/9-(methyl-carbonyl)-bases. As an 
example we report here the synthesis of the Mmt thymine linker (Scheme 5), obtained 
by coupling the new backbone 18 with carboxymethylated thymine 11 to give 19, 
followed by saponification in standard conditions, which afforded the desired Mmt-t 
linking monomer 20 with an overall yield of 80%. Considering the Mmt-Cl amount used 
in the first step of the synthetic strategy, the overall yield of Mmt-t linking monomer 20 
resulted to be 65%, higher than previously obtained.25,26 The new O-Mmt backbone 18 
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can be easily used also to synthesize PNA-3'DNA linkers containing the other bases in 
analogy to Mmt/acyl PNA monomers (12, 13, 14). 
The new linking backbone 18 and the corresponding t linker monomer 19 were 
characterized on the basis of their 1H and 13C NMR spectra. 
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Scheme 5. 
 
N-(2-(4-Methoxyphenyl)diphenylmethoxyethyl)glycine methyl ester 18 (Scheme 4).  
Chlorohydrate salt of 2-aminoethanol (16, 120 mg, 1.28 mmol, 4 eq) was dissolved in 
dry DMF (2 ml) and cooled at 0 °C. Mmt-Cl (99 mg, 0.32 mmol, 1 eq) in dry pyridine (1 
ml) was added under stirring in portions and the solution was allowed to warm to room 
temperature. After 16 h, the reaction was quenched by adding few drops of methanol, 
evaporating to dryness and extracting with H2O/CH2Cl2 (1% TEA). A small amount of 
crude product (2-(4-methoxyphenyl)-diphenylmethoxy)ethylamine 17 was loaded on a 
chromatographic column and eluted with increasing amounts (15-20%) of AcOEt in 
CH2Cl2 (1% NEt3) as eluent to check for the identity by NMR; yellow oil; Rf =0.14 (85:15 
CH2Cl2/MeOH); H (CDCl3) 2.87 (2 H, t, J 5.2, CH2), 3.14 (2 H, t, J 5.2, CH2), 3.78 (3 H, 
s, Mmt-OMe), 7.19-7.46 (14 H, m, Mmt); C (CDCl3) 42.3 (CH2NH2), 55.2 (Mmt-OCH3), 
65.6 (CH2O), 86.1 (CAr3), 113.0 (C-7’), 126.8 (C-4’), 127.7 (C-3’), 128.4 (C-2’), 130.3 (C-
6’), 135.9 (C-5’), 144.6 (C-1’), 158.5 (C-8’); The remaining crude product 17 was 
dissolved in dry CH2Cl2 and Et3N (535 µl, 3.85 mmol, 12 eq) and directly reacted with 
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BrCH2COOMe (35 µl, 0.384 mmol, 1.2 eq). After 2 h the reaction was complete and was 
quenched by adding water. Crude material was extracted by H2O/CH2Cl2 (1% TEA) and 
separated by silica gel chromatography using increasing amounts (15-20%) of AcOEt in 
CH2Cl2 (1% NEt3) as eluent, giving pure sample of 18 (103 mg, 0.256 mmol, 80% overall 
yield) as a yellow oil; Rf =0.22 (8:2 CH2Cl2/AcOEt); H (CDCl3) 2.03 (1 H, s, NH), 2.82 (2 
H, t, J 5.4, CH2), 3.21 (2 H, t, J 5.4, CH2), 3.42 (2 H, s, CH2CO), 3.73 (3 H, s, COOMe), 
3.79 (3 H, s, Mmt-OMe), 7.46-6.81 (14 H, m, Mmt); C (CDCl3) 49.2 (CH2CO), 50.7 
(CH2NHCH2), 51.7 (COOCH3), 55.1 (Mmt-OCH3), 62.8 (MmtOCH2), 86.2 (CAr3), 113.3 
(C-7’), 127.0 (C-4’), 128.0 (C-3’), 128.6 (C-2’), 130.5 (C-6’), 136.0 (C-5’), 144.8 (C-1’), 
158.7 (C-8’), 173.0 (COOMe); m/z (MALDI-TOF) found 406 (M + H+), C25H27NO4 + H+
requires 406.5. 
 
N-(2-(4-Methoxyphenyl)diphenylmethoxyethyl)-N-((1-thyminyl)acetyl glycine methyl ester 
19 (Scheme 5). 
To a solution of carboxymethyl thymine (11, 55 mg, 0.30 mmol, 1.2 eq) in dry DMF (2 
ml), HOBt (40 mg, 0.30 mmol, 1.2 eq) was added followed by NMM (60 µl, 0.55 mmol, 
2.2 eq) and a solution of the backbone 18 (100 mg, 0.250 mmol, 1.0 eq) in 2 ml of dry 
DMF whilst stirring. Finally, DIC (50 µl, 0.325 mmol, 1.3 eq) was added whilst stirring. 
After 20 h the reaction mixture was quenched by adding few drops of water and 
evaporating in vacuo. The residue, dissolved in AcOEt, was washed by water and the 
organic extract, evaporated under reduced pressure, was purified by chromatography on 
a silica gel column eluted with increasing amounts of AcOEt in CH2Cl2 (1% TEA), to give 
119 mg (0.210 mmol, 84%) of 19 as a yellow oil; Rf = 0.46 (96:4 CH2Cl2/MeOH); H
(CDCl3) 1.81 and 1.90 (3 H, 2xs [2 rotamers], H-5 T), 3.31 and 3.41 (2 H, 2xm [2 
rotamers], NCH2), 3.54 (2 H, m, MmtOCH2), 3.67 (3 H, s, COOMe), 3.79 (3 H, s, Mmt-
OMe), 3.98 and 4.35 (2 H, 2xs [2 rotamers], CH2COOMe), 4.42 and 4.72 (2 H, 2xs [2 
rotamers], CH2CON), 6.64-7.39 (15 H, m, Mmt, H-6 T), 8.77 and 8.86 (2 H, 2xs [2 
rotamers], H-3 T); C (CDCl3) 12.27 and 12.29 (thymine CH3), 47.4 and 47.5 
(CH2N(CO)CH2), 47.9 and 48.5 (N(CO)CH2CO), 48.3 and 50.4 (N(CO)CH2N), 52.3 and 
52.6 (COOCH3), 55.2 (Mmt-OCH3), 61.0 and 62.6 (MmtOCH2), 87.0 and 87.7 (CAr3), 
110.5 and 110.6 (thymine C5), 113.2 and 113.3 (C-7’), 127.0 and 127.3 (C-4’), 127.9 
and 128.1 (C-3’), 128.2 and 128.4 (C-2’), 130.3 and 130.4 (C-6’), 134.8 and 135.2 (C-
5’), 140.8 and 140.9 (thymine C6), 143.7 and 144.2 (C-1’), 150.89 and 150.94 (thymine 
C2), 158.6 and 158.8 (C-8’), 164.1 and 164.2 (thymine C4), 167.2 and 167.4 
(N(CO)CH2N), 169.0 and 169.6(COOMe); m/z (MALDI-TOF) found 594 (M + Na+), 
C32H33N3O7 + Na+ requires 594.6. 
 
Tetrabutylammonium N-(2-(4-methoxyphenyl)diphenylmethoxyethyl)-N-((1-
thyminyl)acetyl) glycinate 20 (Scheme 5). 
 
To a solution of compound 19 (119 mg, 0.210 mmol) in dioxane (3 ml) a solution of 
tetrabutyl ammonium hydroxide (2 M) was added dropwise until the solution reached pH 
12. After 2 h the solution was adjusted to pH 7 by the dropwise addition of 2 M aqueous 
KHSO4. After evaporation the residue was resuspended in CH2Cl2 and filtered. The 
filtrate evaporated under reduced pressure resulted to be the desired compound 20 (158 
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mg, 0.199 mmol) in 95% yield; Rf =0.44 (9:1 CH2Cl2/MeOH); H (CDCl3) 0.97-1.64 (28 H, 
m, butyl), 1.82 and 1.85 (3 H, 2xs [2 rotamers], H-5 T), 2.34 and 2.41 (2 H, 2xm [2 
rotamers], NCH2), 3.19 (8 H, m, butyl NCH2), 3.43 and 3.56 (2 H, 2xm [2 rotamers], 
MmtOCH2), 3.78 (3 H, s, Mmt-OMe), 3.90 and 4.01 (2 H, 2xs [2 rotamers], CH2COO-), 
4.45 and 4.88 (2 H, 2xs [2 rotamers], CH2CON), 6.77-7.44 (15 H, m, Mmt, H-6 T), 8.64 
(1 H, s, H-3 T); m/z (MALDI-TOF) found 580 (M + Na+), C31H31N3O7 + Na+ requires 
580.6. 
 
In conclusion in this section we described a new synthetic strategy to synthesize a Mmt 
protected PNA-3'DNA linker useful for connecting the PNA part of PNA/DNA chimeras to 
3' end of the DNA one. 
Mmt protected hydroxyethylglycine 18 (Scheme 4), conveniently obtained in two 
synthetic steps starting from chlorohydrate salt of 2-aminoethanol, was coupled to the 
carboxymethyl thymine 11 to give the monomer 19 in a very good overall yield (Scheme 
5). 
Furthermore, a convenient method for the preparation of PNA monomers with 
monomethoxytrityl (Mmt) group as temporary protection of the backbone amino function 
and acylic protection on the nucleobases was employed. We followed a general strategy 
that relies on the coupling between Mmt protected N-(2-amino-ethyl)-glycine ester 
(backbone) and protected N1/9-(methyl-carbonyl)-bases. The Mmt protected backbone 
3 was obtained from ethylenediamine 1 in two synthetic steps with an overall yield (65%) 
higher than previously obtained (Scheme 1).22 
The synthesis of the desired protected N1/9-(methyl-carbonyl)-bases was accomplished 
according to reported procedures.22 However, we have obtained an improvement in the 
reactions between protected cytosine 4 and protected adenine 6 with methyl 
bromoacetate in respect to those previously reported in literature.22 We got better yields 
as compared to those reported in literature22 also in the condensations between the 
N1/N9-carboxymethylated bases 9 and 10 and the backbone 3 to give the monomers 13 
and 14 (Scheme 3). 
The main advantage of the synthetic procedures to obtain both the Mmt backbone 3 and 
the Mmt hydroxyethylglycine 18 is the introduction of the acid labile Mmt protecting 
group in the first step. 
The strategies described herein thus easily allows a cheap and large scale preparation 
of the monomers for the automatic synthesis of PNA/DNA chimeras using the 
convenient Mmt chemistry. 
 
1.3.6 Synthesis of PNA/DNA chimeras 
 
The PNA/DNA chimeras oligomers were assembled with the PNA section at the 3'-end 
(C-terminus, Fig. 2 ) and the DNA part at the 5'-end. A glycine residue was loaded on a 
Controlled-Pore Glass (CPG, loading 49imol/g ) resin by using DIC/DMAP as activating 
system (R.T., 16 h). Glycine loading was checked by UV detection of removed Fmoc 
group and was always more than 95%. Subsequently PNA monomers were added 
manually and swelling of the resin during each synthetic step was provided by means of 
a vibrating shaker. PNA monomer coupling was carried out in DMF/MeCN solution using 
NMM as base and PyBOP as activating reagent (two couplings of 20 min). The modified 
PNA thymine linker monomer bearing the monomethoxytrityloxyethyl group has been 
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used to connect the PNA part to the DNA one ( 22 ). After each coupling, capping of 
unreacted amino groups was achieved using a mixture of acetic anhydride (5%) and 
lutidine (6%) in DMF. Coupling efficiency was evaluated by spectroscopic 
measurements of monomethoxytrityl cation release after deprotection with 3% TCA in 
DCM (yields between 90-95%). The assembly  of DNA part was performed on an 
Expedite 8909 automated DNA/PNA synthesiser on the 15 µmol scale by a standard 
synthetic cycle, consisting of double coupling with the 5’-DMT-nucleoside-3’-
phosphoramidite, capping of the unreacted 5’-OH functionalities and oxidation of the 
P(III) to P(V) with final DMT removal. DNA coupling efficiency was automatically 
monitored  by the measurement of 4,4’-dimethoxytrityl cation released by the acid 
treatment of each deblock step. Deprotection of the nucleobase protecting groups and 
detachment of the chimeric oligomers from the solid support were achieved by treatment 
with a solution of KOH (0.4 M) in MeOH:H2O (4:1) for 17 h at R.T. The supernatant was 
filtered and the support  washed with H2O (3x4 ml). The combined filtrate and washings 
were concentrated in vacuo and redissolved in water. 
 
1.3.7 HPLC purification of PNA-DNA chimeras 
 
The crude chimeric oligomers were analysed and purified by HPLC on a Nucleogel SAX 
column (Machery Nagel SAX 1000-8 4.6x50 mm, SAX 1000-10 25x150 mm) eluted with 
linear gradients of KCl (0-70%) in 20 mM K2HPO4, pH 7.0, 20% CH3CN. 
Analytical HPLC for Chim 18 mer (crude material): 
 
0-100% B 40 min (analytical SAX column ) 
 
Analytical HPLC Chim 20 mer (crude material): 
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0-100% B 40 min (analytical SAX column)  
 
The isolated oligomers (20 mer and 18 mer) having both a retention time of about 27 
min, were desalted by Sephadex gel filtration on NAPTM-25 columns eluted with water 
and analysed by LC ESI-MS (experiments performed on Finnigan Surveyor MSQ™ 
LC/MS Mass Spectrometer). Around 25 mg of chimeric oligomer were recovered in both 
cases after this procedure corresponding to a 20 % yield. Chim 20: m/z (ESI) found 
1521.4 [M + 4H]4+, 1215.9 [M + 5H] 5+ require 1520.6 [M + 4H]4+, 1216.7 [M + 5H] 5+;
Chim 18: m/z (ESI) found 1844.6 [M + 3H]3+, 1384.3 [M + 4H]4+, 1107.7 [M + 5H] 5+ 
require 1845.4 [M + 3H]3+, 1384.3 [M + 4H]4+, 1107.6 [M + 5H] 5+. By HPLC analysis on 
analytical column the isolated oligomers resulted to be more than 98% pure. 
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Figure 20: LC-ESI MS allows for checking identity of chimeras 
 
1.3.8 UV melting studies of the chimeric duplex 
 
The chimeric molecules were annealed in a solution consisting of 100 mM NaCl (pH 7.0) 
by heating the mixture at 90 °C for 5 min and allowed to cool at R.T overnight. Ultraviolet 
melting temperatures ( T m ) at d= 260 nm on this solution were determined using a 
JASCO V-550 UV/VIS spectrophotometer equipped with a Peltier block. A heating rate 
of 0.5 °C/min was used throughout. 
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Figure 21: UV Melting (0.5 °C/min) of duplex Chim 2A (10 µM), 100 mM NaCl, cuvette 
1mm. 
 
Experiments were repeated until three values within 0.5 °C of each other were obtained. 
Molar extinction coefficients used for DNA bases were as follows: A, 15.4; T, 8.8; G, 
11.7; C, 7.3 mM-1. Molar extinction coefficients used for PNA bases were T, 8.6; C, 6.6 
mM-1. T m value (43.9 °C) was determined from the maximum of the first derivative of the 
plot of A 260 versus temperature.  
CD profile for the chimeric duplex is reported below. Parameters used in this experiment 
were: scanning speed = 50 nm/min; cell Length= 1 cm; concentration= 2 µM; solvent= 
tamp 5mM pH7 0.5mM Mg Temperature = 15 °C. 
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1.3.9 Stability of bent Nucleic Acids and PNA-DNA chimeras in Human Serum at 37 °C 
 
The stability of the double-stranded PNA-DNA chimera molecule with 2 adenines in the 
bulge (chim 2A) was tested in human serum in comparison with 2A, the double-stranded 
DNA. 
7 iM Chim 2A (as checked by UV absorption) was incubated at 37 °C in 100% fresh 
human serum and 10 ul of the solution was injected on Sax analytical column in HPLC 
experiments (A = 20 mM K2HPO4, pH 7.0, 20% CH3CN; B = KCl 1M, 20 mM K2HPO4,
pH 7.0, 20% CH3CN). The diminution of the area of the HPLC peak corresponding to the 
undegraded molecule after different incubation times in serum was checked in order to 
follow the degradation of 2A. 
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Figure 22: HPLC profile of 100% fresh human serum (analytical Sax column, 0-100% B 
in A in 25 min). 
 
Figure 23: HPLC profile of 7 iM Chim 2A incubated at 37 °C in 100% fresh human 
serum (t = 30 min). 
 
Retention Time Area % Area 
1 0,649 1770157 20,33
2 1,377 347521 3,99
3 4,825 13912 0,16
4 5,672 367644 4,22
5 7,796 5265773 60,47
6 9,774 132553 1,52
7 10,838 11904 0,14
8 11,571 120580 1,38
Retention Time Area % Area 
1 0,654 1545290 9,00
2 0,807 1125594 6,56
3 1,151 914941 5,33
4 1,596 697238 4,06
5 2,289 85087 0,50
6 5,093 1253072 7,30
7 7,211 9957945 58,03
8 9,338 326700 1,90
9 11,396 114148 0,67
10 17,179 1111755 6,48
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Figure 24: HPLC profile of 7 iM Chim 2A incubated at 37 °C in 100% fresh human 
serum (t = 24 h). 
 
Retention Time Area % Area 
1 0,687 7341081 19,70
2 1,351 2011804 5,40
3 5,777 2275586 6,11
4 6,859 338108 0,91
5 7,993 20249236 54,35
6 9,592 2067249 5,55
7 10,197 602727 1,62
8 10,690 880515 2,36
9 11,656 981639 2,63
10 12,325 144454 0,39
11 13,768 34508 0,09
12 16,902 305438 0,82
Retention Time Area % Area 
1 0,608 4757473 31,37
2 1,210 623890 4,11
3 5,549 381956 2,52
4 7,369 459964 3,03
5 8,085 8255918 54,43
6 9,175 85241 0,56
7 9,591 212881 1,40
8 11,684 183174 1,21
9 16,998 206395 1,36
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Figure 25: HPLC profile of 7 iM Chim 2A incubated at 37 °C in 100% fresh human 
serum (t = 40 h). 
 
The HPLC peak areas relative to the Chim 2A, expressed as percentage of the total 
HPLC profile area to avoid inaccuracies due to different injection volumes, was reported 
in function of the incubation times (see Fig. 26). The non-linear regression analysis 
curve (R2 = 0.99) gave, by interpolation, a 50% degradation time of 9 h. On the other 
hand, 2A DNA duplex has a 40 min half-life, and was completely degraded after 1h 35 
min.  
 
Figure 26: Serum degradation curve for Chim 2A in human fresh serum. 
 
1.3.10 Biological Assays: proliferation assay, migration assay and in vivo test 
 
To investigate whether the chimeric bent duplex was able to inhibit in vitro the HMGB1 
induced proliferation and migration activities of bovine aortic endothelial cells (BAEC), 
two biological assays were performed: the proliferation and the chemotaxis assays. 
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Figure 27: Bovine Aortic Endothelial Cells (BAEC). 
 
Proliferation Assay  
 
The proliferation assay was performed as described by Palumbo et al., (2004). BAEC 
cells (bovine aortic endothelial cells) were seeded in 6-well plates (105 cells/well) and 
grown in RPMI medium supplemented with 20% FCS. After 24 h, the medium was 
replaced with serum-free RPMI and cells were then starved for 16 hours to synchronize 
the cell population. Vehicle (negative control or basal proliferation) or 30 ng/mL (1 nM) of 
HMGB1 (bacterially made) were added in the presence or in the absence of 100 nM of 
the test compounds (dissolved and diluted in serum-free medium).  
 
63 
Figure 28: Effect of HMGB1-Chimeric duplex interaction on cellular (BAEC) proliferation 
 
The assay performed  with the bent Chim 2A was also carried out with a control linear 
oligo DNA (indicated as ss oligo in the legend of Figure 28), consisting of the 20 mer 
strand. The experiment was repeated three times. BAEC cell proliferation was 
determined by detaching the cells from the plate at the indicated times, and counting the 
Trypan-blue excluding cells under the microscope. The inhibition of the HMGB1-induced 
proliferation activity of BAEC cells by the bent chimeric compound are shown in Figure. 
In a further assay according to the protocol as described above, it was demonstrated 
that the bent chimeric duplex concentration-dependently inhibit/antagonize the 
proliferation of BAEC cells induced by HMGB1.  
The highest proliferation effect was recorded in serum free cells treated with HMGB1 (25 
ng/mL) after 72 hours.  When serum free cells are treated with HMGB1 (25 ng/mL) and 
Chim 2A (100 ng/mL) the proliferation effect is basal and similar to that showed by 
serum free untreated cells. 
The Chim 2A exhibited an IC50 of 10 nM, while control linear duplex DNA does not 
(Figure 10/Table 1). In a further experiment , proliferation of BASMC (bovine aortic 
smooth muscle cells) in the presence of the specific compounds of the present work was 
tested (protocol described in Palumbo et al., 2004, not shown data). BASMC cells were 
seeded in 6-well plates (105 cells/well) and grown in RPMI medium supplemented with 
20% FCS. After 24 h, the medium was replaced with serum-free RPMI and cell were 
then starved for 16 hours to synchronize the cell population. Vehicle (negative control or 
basal proliferation) or 25 ng/mL (1 nM) of HMGB1 (bacterially made) were added in the 
presence or in the absence of the compounds dissolved as described above. Each 
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experimental point represents the mean +/- SD of triplicate determinations. The 
experiment was repeated three times. BASMC cell proliferation was determined by 
detaching the cells from the plate at different times (on days 1, 2, 3 and 4 of culturing) 
and counting the Trypan-blue excluding cells under the microscope. A concentration 
dependent inhibition of proliferation of BASMC was observed for the bent duplex (IC50 
10 nM). The linear control compounds had no effect. 
 
Chemotaxis Assay 
 
Chemotaxis assays were performed using well-known protocols, in particular as 
described by Palumbo et al., (2004). 
Modified Boyden chambers were used with filters having 5-8 µm pore size and treated 
with gelatine type A from porcine skin 5 µg/mL. BAEC cells were resuspended in serum-
free DMEM (Dulbecco’s Modified Eagle’s Medium) and a sample of 40,000 cells was 
added to the upper well of a Boyden chamber.  
 
Figure 29: Boyden chamber for chemotaxis assays 
 
The molecules to be tested were dissolved and diluted in the same serum-free medium 
and added to the lower well of the chamber; HMGB1 (bacterially made) concentration 
was 25 ng/mL, for test compounds it was 3-100 nM. The assay performed with bent 
Chim 2A was also carried out with a single strand (20 mer) as indicated above as control 
compound. Cell migration was allowed at 37 ± 0.5 °C for 4 hours, then cells were 
scraped off the upper surface, and filters were fixed in ethanol and stained in a solution 
of modified Giemsa stain (Accustain, Sigma).  
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Figure 30: Effect of HMGB1-Chimeric duplex interaction on cellular migration 
 
All experiments were performed at least twice in triplicate. The inhibition of HMGB1-
induced migration activity of BAEC cells by the bent chimeric compound is shown in 
Figure 6. Results are the mean +/- SD of the number of cells counted in 10 high power 
fields per filter. In absence of HMGB1 cell migration  was only basal (migration index
5,0 cells/field). When HMGB1 is present at a concentration of 25 ng/mL, cells migrate 
significantly (30 cells/field). A similar migration is observed when cells are treated with 
25 ng/mL HMGB1 and different amounts (3/10/30/100 nM) of control single strand. In 
this case, since single strand does not present the same ability of Chim 2A bent 
structure to interact with HMGB1, no effect was expected. On the other hand, when 
cells, incubated with HMGB1 (25 ng/mL), are treated by Chim 2A, a concentration 
dependent inhibition of migration of BAEC cells is observed (IC50 10 nM). 
 
In vivo tests 
 
Several in vivo tests based on the reversal of LPS-induced endotoxemia in mice are in 
progress and preliminary results show that mortality significantly decreases as a 
consequence of the treatment with PNA/DNA chimeras.  
 
1.3.11 Conclusions and perspectives  
 
This thesis shows that it is possibile to use oligonucleotidic ligands  to target pro-
inflammatory cytokines like HMGB1. By improving the synthesis and purification of both 
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monomers and chimeric oligomers, it was possible to obtain enzymatically stable 5’DNA-
3’PNA chimeras in large scale and high purity. The obtained quantities of pure chimeras 
allowed us to use these molecules for the first time in vivo in experiments that showed 
that chimera-chimera duplexes are able to interact with HMGB1 blocking its important 
pro-inflammatory effects.  
Future efforts will be focused on improving this strategy by shortening chimeric 
sequences. Another approach to be explored will deal with duplexes having two different 
nucleobases in the bulge or an abasic. Subsequently, other DNA analogues different 
from PNA will be used for realising new chimeric structures to be used for the same 
biotechnological application described in this thesis.  
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PART 2  
 
New nucleoamminoacids useful for applications of PNA/DNA chimeras in the 
diagnostic field  
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2.1 Introduction 
 
The unambiguous and fast detection of oligonucleotide sequences in vitro and in vivo still 
is a major market especially since more and more diseases are linked to their genetic 
origin. In 1996 Kramer introduced the concept of a molecular beacon (Figure 1A)[1] as one 
of many diagnostic methods for DNA single strand sequence detection as well as 
mismatch identification known so far.[2] The molecular beacon is a DNA single strand 
composed of a loop region having a length of around 20 nucleotides with a sequence 
complementary to the target DNA and a stem region in which the terminal nucleotides 
(around 10) are paired in a double strand.[3] On the 5'- or 3'-terminus, respectively, a 
fluorophore and a quencher are linked. Fluorescence is quenched as long as the stem 
region is paired in a double strand. Recognition of the target DNA by formation of a rigid 
helical double strand leads to separation of the termini which can be easily detected by 
fluorescence. Next to genetic analysis[4] and detection of point mutations, the molecular 
beacon concept is also of use in real time PCR,[1] RNA detection in living cells,[5] and in the 
identification of protein-DNA interactions.[6] The introduction of single molecule detection 
for the interaction of a molecular beacon with DNA leads to an increase in sensitivity from 
about 10-7 M to 10-11 - 10-12 M.[7] Nevertheless, the sensitivity based on this detection is 
limited due to the solvent accessibility of the fluorophore. 
 
Figure 1. A. Concept of a molecular beacon as described by Kramer;[1] B. Molecular 
beacon composed of an alanyl-PNA stem hiding the fluorophore (F) within the nucleobase 
stack and DNA recognition loop.  
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2.2 The molecular beacon approach for DNA single strand sequence detection 
 
In order to gain even higher sensitivity for DNA detection, we propose to use an alanyl-
PNA double strand as the stem of a molecular beacon keeping the DNA recognition loop 
(Figure 1B). Alanyl-PNA is an artificial oligomer that forms specific and stable double 
strands based on nucleobase recognition.[8] The alanyl-PNA pairing system is orthogonal 
to oligonucleotides with respect to double strand formation and provides a possibility to 
hide the fluorophore from polar solvents.[9] 
 
Figure 2. Linear alanyl-PNA double strand: a fluorophore can be hidden within the 
nucleobase stack covalently linked to an alanyl side chain instead of a nucleobase. 
 
An alanyl-PNA oligomer is based on a regular peptide backbone composed of alanyl 
amino acids that carry covalently linked nucleobases in the ]-position of the side chain 
(Figure 2).[10] Oligomerization of the nucleo amino acids allows for the formation of rigid 
and well defined double strands with linear topology based on base pair recognition, 
stacking, and solvation. Base pairs are stacking with a distance of about 3.5 Å providing a 
completely extended peptide backbone. Nevertheless, intercalation can be made possible 
by creating oligomers with a missing base pair by introduction of glycines in opposite 
positions.[11] Evidence for a non-polar environment within the basestack of alanyl-PNA is 
derived from a stabilizing effect from incorporation of aromatic amino acids in alanyl-
PNA.[9] Shielding of the fluorophore from the water environment when intercalated within 
the alanyl-PNA duplex should be a major advantage of the chimeric alanyl-PNA/DNA 
molecular beacon. To ensure for a stoichiometrically well defined system, the fluorophore 
will be covalently linked to the peptide backbone. Guanine nucleobases in the 
complementary alanyl-PNA strand will function as quenchers.[7] 
A molecular beacon composed of an alanyl-PNA stem and a DNA recognition part 
requires the preparation of alanyl-PNA/DNA/alanyl-PNA chimeras (Figure 3A). They might 
be obtained either by ligation of two alanyl-PNA fragments to the 3'- and 5'-termini of the 
DNA single strand, respectively,[12,13] or by solid phase synthesis of the whole chimeric 
strand under DNA synthesis conditions.[14] Uhlmann and van Boom already reported the 
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stepwise solid phase synthesis of aminoethylglycine-PNA/DNA chimeras (Figure 3B)[15,16] 
adapting the protecting group strategy for nucleo amino acids to DNA synthesis conditions. 
The protecting groups of the nucleo amino acids need to be compatible with the DNA 
phosphoramidite chemistry: the acid labile monomethoxytrityl (Mmt) protection and the 
acyl protecting groups on the exocyclic amino functions of the nucleobases are suitable for 
this purpose. The Mmt-protected monomers show good solubility in the polar organic 
solvents (e.g. DMF) used for the synthesis of the oligomers and the conditions for 
removing the Mmt protecting group (3% trichloroacetic acid) are mild and do not cause 
depurination in the DNA portion of the chimeras. Moreover, in the peptide synthesis by 
Mmt-chemistry every coupling can be monitored by measuring the absorbance of Mmt+ ion 
released in acid (q478=65000) allowing the evaluation of the coupling yield. 
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2.3  Alanyl-PNA double strand as the stem of a molecular beacon  
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Figure 3. A. Alanyl-PNA/DNA/Alanyl-PNA chimera and B. aminoethylglycine-
PNA/DNA/aminoethylglycine-PNA chimera as described by Uhlmann.[15] 
In this work the enantioselective preparation of Mmt-protected nucleo amino acids 1–4 
(Figure 4) was provided by the syntheses of Boc-alanyl nucleo amino acids[17,18] followed 
by a substitution of the terminal amino protecting group. Nevertheless, the need for acyl 
protection of the nucleobases afforded a reinvestigation of the Boc-amino acid synthesis 
with the respective nucleobase. 
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Figure 4. Mmt/acyl-protected nucleo amino acids for the synthesis of alanyl-PNA/DNA 
chimeras. 
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2.4 Synthesis of Mmt-protected alanyl nucleo amino acids. 
 
Boc-protected alanyl nucleo amino acids are obtained by ring opening of Boc-serine 
lactone (5)[19] with the respective nucleobase (Scheme 1).[17,18] Since thymine is the only 
nucleobase that does not require protection, nucleo amino acid 6 was obtained as 
described in literature.[17] The acyl-protected nucleobases 8, 9 and 11 were synthesised 
according to the procedure described by Will et al.[15] N-Boc-	-[N6-(Anisoyl)adenin-9-
yl]alanine (7) was provided in 32% yield by ring opening of Boc-serine lactone 5 with N6-
anisoyladenine (8) in DMSO with DBU as a base. As known already for the reaction with 
the unprotected nucleobases, the yield of the serine lactone ring opening with nucleobases 
is quite low (22% in case of adenine)[18] because of their low solubility, regioselectivity 
problems (N7 vs. N9 alkylation and SN2 vs. carbonyl attack on the serine lactone), 
polymerization of the serine lactone, and racemization. Nevertheless, despite intensive 
studies for improvement in the yield for this reaction, this route turned out to be most 
efficient. The enantiomeric purity was investigated for nucleo amino acid 7 (92% ee) as 
well as for all other derivatives described herein by Boc-deprotection followed by dipeptide 
formation with the Boc-L-Ala-OSu active ester and HPLC analysis of the respective 
diastereomers. N4-(4-tert-Butylbenzoyl)cytosine (9) was also converted to the N-Boc-	-
[N4-(4-tert-butylbenzoyl)cytosin-1-yl]alanine (10) in DMSO in presence of DBU with 
moderate yield (42%) but excellent enantiomeric purity (99% ee). 
N-Boc-	-[N2-(isobutyryl)guanin-9-yl]alanine (11) was provided with an optical purity of 
96% ee in 29% yield by ring opening of Boc-serine lactone 5 with N2-(isobutyryl)guanine 
(12) in DMSO and DBU as base. 
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Scheme 1. Synthesis of Boc and Mmt protected nucleo amino acids with acyl protected 
nucleobases.  
 
Mmt-protected nucleo amino acids 1–4 were obtained starting from the respective Boc-
derivatives 6, 7, 10 and 11 by Boc-deprotection with TFA and immediate tritylation of the 
free nucleo amino acids with monomethoxytrityl chloride (MmtCl) in DMF in presence of 
triethylamine (Scheme 1). The desired protected monomers were directly obtained by 
precipitation from diethyl ether at -28 °C. This straightforward route was chosen even 
because silica gel chromatography of the Mmt-amino acids making use of acidic eluents 
for protonating the carboxylate moiety causes the deprotection of the acid labile trityl 
protection. Experimental procedures for this synthetic route are described by Roviello et 
al20.
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2.5 Conclusions and perspectives 
 
The enantioselective preparation of all canonical alanyl nucleo amino acids with Mmt-
protected [-amino groups and acyl-protected exocyclic amino functions of the 
nucleobases was presented in this work. It was made possible by the synthesis of the 
respective N-Boc nucleo amino acids carried out by adapting the synthetic routes to the 
Boc-protected alanyl amino acids in the case of the acyl-protected nucleobases. These 
derivatives will be advantageous in the solid phase synthesis of alanyl-PNA/DNA chimeras 
which might serve as tools for very sensitive DNA detection following the molecular 
beacon concept. Oligomer synthesis and functional evaluation are currently under 
investigation. 
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